社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
IcyAlchemist
IP属地:未知
+关注
帖子 · 148
帖子 · 148
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
IcyAlchemist
IcyAlchemist
·
2021-12-13
Like and comment
2 Top Biotech Stocks To Buy Right Now
Growing global demand for prescription drugs in the years ahead bodes well for these two stocks. Buy them now while they're still cheap.
2 Top Biotech Stocks To Buy Right Now
看
1,804
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
IcyAlchemist
IcyAlchemist
·
2021-12-13
Like and comment
OPEC upbeat on 2022 oil demand, says Omicron impact to be mild
OPEC on Monday raised its world oil demand forecast for the first quarter of 2022 but left its full-
OPEC upbeat on 2022 oil demand, says Omicron impact to be mild
看
3,416
回复
评论
点赞
1
编组 21备份 2
分享
举报
IcyAlchemist
IcyAlchemist
·
2021-12-13
Like and comment.
Toplines Before US Market Open on Monday
U.S. stock-index futures pointed to muted gains for major indexes ahead of a busy week of central-ba
Toplines Before US Market Open on Monday
看
1,540
回复
1
点赞
2
编组 21备份 2
分享
举报
IcyAlchemist
IcyAlchemist
·
2021-12-12
Like and comment
Is Inflation Going to Cool Down Anytime Soon?
Two Motley Fool contributors discuss the issue weighing on a lot of people's minds.
Is Inflation Going to Cool Down Anytime Soon?
看
3,121
回复
1
点赞
4
编组 21备份 2
分享
举报
IcyAlchemist
IcyAlchemist
·
2021-12-12
Like and comment
US IPO Week Ahead: IoT solutions, wine, and satellites in a 3 IPO week
The IPO market is expected to stay relatively quiet in the week ahead with three IPOs scheduled to r
US IPO Week Ahead: IoT solutions, wine, and satellites in a 3 IPO week
看
2,543
回复
1
点赞
3
编组 21备份 2
分享
举报
IcyAlchemist
IcyAlchemist
·
2021-12-09
Like and comment
2 Short-Squeeze Candidates That Could Go Parabolic Soon
Cortexyme and Heron Therapeutics are two of the most heavily shorted biopharma stocks right now.
2 Short-Squeeze Candidates That Could Go Parabolic Soon
看
2,291
回复
2
点赞
1
编组 21备份 2
分享
举报
IcyAlchemist
IcyAlchemist
·
2021-12-09
Like and comment
10 Biggest Price Target Changes For Thursday
SVB Leerink boosted the price target on Edwards Lifesciences Corporation from $130 to $135. Edwards
10 Biggest Price Target Changes For Thursday
看
1,829
回复
3
点赞
7
编组 21备份 2
分享
举报
IcyAlchemist
IcyAlchemist
·
2021-12-08
Really?
GameStop Stock Could Soar After Its Recent Plunge. Here's Why.
Down more than 25% since late November, here’s what could happen next for the original meme stock. A
GameStop Stock Could Soar After Its Recent Plunge. Here's Why.
看
1,345
回复
2
点赞
4
编组 21备份 2
分享
举报
IcyAlchemist
IcyAlchemist
·
2021-12-08
Like and comment
Waymo's slow-going in Arizona opens up U.S. robotaxi race
CHANDLER, Ariz., Dec 8 (Reuters) - Alphabet Inc's Waymo risks losing its lead in the U.S. race to pr
Waymo's slow-going in Arizona opens up U.S. robotaxi race
看
3,185
回复
1
点赞
4
编组 21备份 2
分享
举报
IcyAlchemist
IcyAlchemist
·
2021-12-08
Like and comment
Toplines Before US Market Open on Wednesday
U.S. futures climbed for a third day after rising the most since March on Tuesday,as investors asses
Toplines Before US Market Open on Wednesday
看
1,454
回复
1
点赞
3
编组 21备份 2
分享
举报
加载更多
暂无关注
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3586429646894350","uuid":"3586429646894350","gmtCreate":1623335813852,"gmtModify":1623335813852,"name":"IcyAlchemist","pinyin":"icyalchemist","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":21,"headSize":310,"tweetSize":148,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":604210548,"gmtCreate":1639401073484,"gmtModify":1639401074510,"author":{"id":"3586429646894350","authorId":"3586429646894350","name":"IcyAlchemist","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586429646894350","idStr":"3586429646894350"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604210548","repostId":"2191600757","repostType":4,"repost":{"id":"2191600757","kind":"highlight","pubTimestamp":1639398749,"share":"https://ttm.financial/m/news/2191600757?lang=&edition=full","pubTime":"2021-12-13 20:32","market":"us","language":"en","title":"2 Top Biotech Stocks To Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2191600757","media":"Motley Fool","summary":"Growing global demand for prescription drugs in the years ahead bodes well for these two stocks. Buy them now while they're still cheap.","content":"<p>There's a concise saying in investing that, when properly applied, can make you a better investor. It is as follows: \"The trend is your friend.\" While it's often ascribed to momentum trading, the quote is arguably more beneficial to long-term investing. That's because while short-term price movements of stocks are really anyone's guess, long-term investing success largely depends on picking high-quality, reasonably priced stocks in growing industries.</p>\n<p>Given that the global pharmaceutical industry is forecasted to grow at nearly 5% annually from $1.3 trillion last year to $1.6 trillion by 2025, leading pharma stocks are set to do well going forward. Here are two biotech bargains you should consider purchasing now before everyone else does.</p>\n<h2>1. AstraZeneca</h2>\n<p>The first biotech stock to buy is <b>AstraZeneca</b> (NASDAQ:AZN). The drugmaker has reported impressive year-to-date growth in both its revenue and its core earnings per share (EPS).</p>\n<p>Excluding the acquisition of the rare-disease drugmaker known as Alexion Pharmaceuticals that closed earlier this year, AstraZeneca's year-to-date revenue jumped 25.4% against the year-ago period to $24.1 billion. This robust revenue growth was driven by several factors. The first was the introduction of the company's COVID-19 vaccine, which chipped in $2.2 billion or 45.4% of AstraZeneca's year-to-date revenue growth, excluding the Alexion acquisition.</p>\n<p>Second, the oncology segment revenue led by Tagrisso, Imfinzi, and Lynparza grew $1.6 billion, or 19%, year-to-date compared to the year-ago period, to $9.7 billion. This contributed to 31.9% of AstraZeneca's year-to-date revenue growth, not counting the Alexion acquisition. Double-digit year-to-date growth rates from the company's CVRM (cardiovascular, renal, and metabolism) and RI (respiratory and immunology) segments more than offset the revenue decline in its other medicines segment, which made up the remainder of AstraZeneca's revenue growth this year.</p>\n<p>Due to AstraZeneca's significantly higher revenue base year to date, its core EPS soared 22% against the prior-year period to $3.59. Better yet, this high overall growth is likely to continue in the medium-term as a result of AstraZeneca's pipeline of 175 projects at various phases of clinical development. That's why analysts are forecasting that the stock will deliver 20%+ annual earnings growth to shareholders over the next five years.</p>\n<p>And investors can snatch up AstraZeneca's 2.5% dividend yield and strong growth prospects at a forward P/E ratio of just 13.8, which is what makes the stock such a great buy at this time.</p>\n<h2>2. Merck</h2>\n<p>The second biotech stock to contemplate purchasing at the present time is <b>Merck</b> (NYSE:MRK). Like AstraZeneca, Merck has had a tremendous year thus far. First, the company's year-to-date total revenue has surged to $35.2 billion, which represents a 15.1% growth rate compared to the year-ago period.</p>\n<p>Merck's oncology segment, headed by its crown jewel Keytruda, was able to grow its year-to-date segment revenue 22.1% over the year-ago period, to $13.8 billion. Strong momentum from each of Keytruda, Lynparza, and Lenvima helped the oncology segment grow its year-to-date revenue by $2.5 billion, which is 54.2% of the company's total year-to-date revenue growth.</p>\n<p>Even with Keytruda accounting for 35.8% of its year-to-date revenue, Merck appears well-prepared for the drug's loss of exclusivity in major markets that will occur in 2028 for a couple of reasons.</p>\n<p>For <a href=\"https://laohu8.com/S/AONE.U\">one</a>, the vaccine segment saw its total year-to-date revenue fly 22% higher compared to the year-ago period, to $7.1 billion. Also, the animal-health segment advanced its revenue by 21.8% year to date against the year-ago period, to $4.3 billion. Simply put, these two segments combined are about as large as the oncology segment and are growing at equally remarkable rates.</p>\n<p>Second, the company just completed its acquisition of Acceleron last month. Through the deal, Merck receives a late-stage pulmonary arterial hypertension drug known as sotatercept that possesses plenty of blockbuster potential. The company also receives 20% to 25% royalties from <b>Bristol Myers Squibb</b> (NYSE:BMY) on the anemia drug known as Reblozyl, which has blockbuster potential in its own right.</p>\n<p>Merck's strong operating fundamentals are expected to continue for the foreseeable future, which is evidenced by the analyst forecast of 15% annual earnings growth over the next five years. When weighed against the forward P/E ratio of just 10, Merck boasts an attractive mix of value and growth. Merck's 3.8% dividend yield is also triple the <b>S&P 500</b>'s 1.3%, which is yet another reason investors should consider the stock.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks To Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks To Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 20:32 GMT+8 <a href=https://www.fool.com/investing/2021/12/13/2-top-biotech-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's a concise saying in investing that, when properly applied, can make you a better investor. It is as follows: \"The trend is your friend.\" While it's often ascribed to momentum trading, the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/13/2-top-biotech-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4516":"特朗普概念","MRK":"默沙东","BMY":"施贵宝","BK4534":"瑞士信贷持仓","BK4532":"文艺复兴科技持仓","BK4559":"巴菲特持仓","BK4007":"制药"},"source_url":"https://www.fool.com/investing/2021/12/13/2-top-biotech-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2191600757","content_text":"There's a concise saying in investing that, when properly applied, can make you a better investor. It is as follows: \"The trend is your friend.\" While it's often ascribed to momentum trading, the quote is arguably more beneficial to long-term investing. That's because while short-term price movements of stocks are really anyone's guess, long-term investing success largely depends on picking high-quality, reasonably priced stocks in growing industries.\nGiven that the global pharmaceutical industry is forecasted to grow at nearly 5% annually from $1.3 trillion last year to $1.6 trillion by 2025, leading pharma stocks are set to do well going forward. Here are two biotech bargains you should consider purchasing now before everyone else does.\n1. AstraZeneca\nThe first biotech stock to buy is AstraZeneca (NASDAQ:AZN). The drugmaker has reported impressive year-to-date growth in both its revenue and its core earnings per share (EPS).\nExcluding the acquisition of the rare-disease drugmaker known as Alexion Pharmaceuticals that closed earlier this year, AstraZeneca's year-to-date revenue jumped 25.4% against the year-ago period to $24.1 billion. This robust revenue growth was driven by several factors. The first was the introduction of the company's COVID-19 vaccine, which chipped in $2.2 billion or 45.4% of AstraZeneca's year-to-date revenue growth, excluding the Alexion acquisition.\nSecond, the oncology segment revenue led by Tagrisso, Imfinzi, and Lynparza grew $1.6 billion, or 19%, year-to-date compared to the year-ago period, to $9.7 billion. This contributed to 31.9% of AstraZeneca's year-to-date revenue growth, not counting the Alexion acquisition. Double-digit year-to-date growth rates from the company's CVRM (cardiovascular, renal, and metabolism) and RI (respiratory and immunology) segments more than offset the revenue decline in its other medicines segment, which made up the remainder of AstraZeneca's revenue growth this year.\nDue to AstraZeneca's significantly higher revenue base year to date, its core EPS soared 22% against the prior-year period to $3.59. Better yet, this high overall growth is likely to continue in the medium-term as a result of AstraZeneca's pipeline of 175 projects at various phases of clinical development. That's why analysts are forecasting that the stock will deliver 20%+ annual earnings growth to shareholders over the next five years.\nAnd investors can snatch up AstraZeneca's 2.5% dividend yield and strong growth prospects at a forward P/E ratio of just 13.8, which is what makes the stock such a great buy at this time.\n2. Merck\nThe second biotech stock to contemplate purchasing at the present time is Merck (NYSE:MRK). Like AstraZeneca, Merck has had a tremendous year thus far. First, the company's year-to-date total revenue has surged to $35.2 billion, which represents a 15.1% growth rate compared to the year-ago period.\nMerck's oncology segment, headed by its crown jewel Keytruda, was able to grow its year-to-date segment revenue 22.1% over the year-ago period, to $13.8 billion. Strong momentum from each of Keytruda, Lynparza, and Lenvima helped the oncology segment grow its year-to-date revenue by $2.5 billion, which is 54.2% of the company's total year-to-date revenue growth.\nEven with Keytruda accounting for 35.8% of its year-to-date revenue, Merck appears well-prepared for the drug's loss of exclusivity in major markets that will occur in 2028 for a couple of reasons.\nFor one, the vaccine segment saw its total year-to-date revenue fly 22% higher compared to the year-ago period, to $7.1 billion. Also, the animal-health segment advanced its revenue by 21.8% year to date against the year-ago period, to $4.3 billion. Simply put, these two segments combined are about as large as the oncology segment and are growing at equally remarkable rates.\nSecond, the company just completed its acquisition of Acceleron last month. Through the deal, Merck receives a late-stage pulmonary arterial hypertension drug known as sotatercept that possesses plenty of blockbuster potential. The company also receives 20% to 25% royalties from Bristol Myers Squibb (NYSE:BMY) on the anemia drug known as Reblozyl, which has blockbuster potential in its own right.\nMerck's strong operating fundamentals are expected to continue for the foreseeable future, which is evidenced by the analyst forecast of 15% annual earnings growth over the next five years. When weighed against the forward P/E ratio of just 10, Merck boasts an attractive mix of value and growth. Merck's 3.8% dividend yield is also triple the S&P 500's 1.3%, which is yet another reason investors should consider the stock.","news_type":1,"symbols_score_info":{"AZN":0.9,"BMY":0.9,"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":1804,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604210953,"gmtCreate":1639400993494,"gmtModify":1639400994551,"author":{"id":"3586429646894350","authorId":"3586429646894350","name":"IcyAlchemist","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586429646894350","idStr":"3586429646894350"},"themes":[],"htmlText":"Like and comment ","listText":"Like and comment ","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604210953","repostId":"1167803518","repostType":4,"repost":{"id":"1167803518","kind":"news","pubTimestamp":1639398916,"share":"https://ttm.financial/m/news/1167803518?lang=&edition=full","pubTime":"2021-12-13 20:35","market":"us","language":"en","title":"OPEC upbeat on 2022 oil demand, says Omicron impact to be mild","url":"https://stock-news.laohu8.com/highlight/detail?id=1167803518","media":"Reuters","summary":"OPEC on Monday raised its world oil demand forecast for the first quarter of 2022 but left its full-","content":"<p>OPEC on Monday raised its world oil demand forecast for the first quarter of 2022 but left its full-year growth prediction steady, saying the Omicron coronavirus variant would have a mild impact as the world gets used to dealing with the pandemic.</p>\n<p>The Organization of the Petroleum Exporting Countries (OPEC) said in a monthly report it expects oil demand to average 99.13 million barrels per day (bpd) in the first quarter of 2022, up 1.11 million bpd from its forecast last month.</p>\n<p>\"Some of the recovery previously expected in the fourth quarter of 2021 has been shifted to the first quarter of 2022, followed by a more steady recovery throughout the second half of 2022,\" OPEC said in the report.</p>\n<p>\"Moreover, the impact of the new Omicron variant is projected to be mild and short-lived, as the world becomes better equipped to manage COVID-19 and its related challenges.\"</p>\n<p>OPEC maintained its forecast that world oil demand will grow by 5.65 million bpd in 2021, after last year's historic decline at the start of the pandemic.</p>\n<p>In 2022, OPEC expects further growth in demand of 4.15 million bpd, unchanged from last month, which will push world consumption above 2019 levels.</p>\n<p>OPEC and its allies, known as OPEC+, are gradually unwinding record output cuts put in place last year. Earlier this month, OPEC+ agreed to boost monthly output by 400,000 bpd in January, despite concern about the new variant.</p>\n<p>The report showed OPEC output in November rose by 290,000 bpd to 27.72 million bpd led by increases in top two producers Saudi Arabia and Iraq and a recovery from outages in Nigeria.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OPEC upbeat on 2022 oil demand, says Omicron impact to be mild</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOPEC upbeat on 2022 oil demand, says Omicron impact to be mild\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 20:35 GMT+8 <a href=https://www.reuters.com/business/energy/opec-upbeat-2022-oil-demand-says-omicron-impact-be-mild-2021-12-13/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>OPEC on Monday raised its world oil demand forecast for the first quarter of 2022 but left its full-year growth prediction steady, saying the Omicron coronavirus variant would have a mild impact as ...</p>\n\n<a href=\"https://www.reuters.com/business/energy/opec-upbeat-2022-oil-demand-says-omicron-impact-be-mild-2021-12-13/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/business/energy/opec-upbeat-2022-oil-demand-says-omicron-impact-be-mild-2021-12-13/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167803518","content_text":"OPEC on Monday raised its world oil demand forecast for the first quarter of 2022 but left its full-year growth prediction steady, saying the Omicron coronavirus variant would have a mild impact as the world gets used to dealing with the pandemic.\nThe Organization of the Petroleum Exporting Countries (OPEC) said in a monthly report it expects oil demand to average 99.13 million barrels per day (bpd) in the first quarter of 2022, up 1.11 million bpd from its forecast last month.\n\"Some of the recovery previously expected in the fourth quarter of 2021 has been shifted to the first quarter of 2022, followed by a more steady recovery throughout the second half of 2022,\" OPEC said in the report.\n\"Moreover, the impact of the new Omicron variant is projected to be mild and short-lived, as the world becomes better equipped to manage COVID-19 and its related challenges.\"\nOPEC maintained its forecast that world oil demand will grow by 5.65 million bpd in 2021, after last year's historic decline at the start of the pandemic.\nIn 2022, OPEC expects further growth in demand of 4.15 million bpd, unchanged from last month, which will push world consumption above 2019 levels.\nOPEC and its allies, known as OPEC+, are gradually unwinding record output cuts put in place last year. Earlier this month, OPEC+ agreed to boost monthly output by 400,000 bpd in January, despite concern about the new variant.\nThe report showed OPEC output in November rose by 290,000 bpd to 27.72 million bpd led by increases in top two producers Saudi Arabia and Iraq and a recovery from outages in Nigeria.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":3416,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604237329,"gmtCreate":1639400832390,"gmtModify":1639400842604,"author":{"id":"3586429646894350","authorId":"3586429646894350","name":"IcyAlchemist","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586429646894350","idStr":"3586429646894350"},"themes":[],"htmlText":"Like and comment. ","listText":"Like and comment. ","text":"Like and comment.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604237329","repostId":"1161576842","repostType":4,"repost":{"id":"1161576842","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639400492,"share":"https://ttm.financial/m/news/1161576842?lang=&edition=full","pubTime":"2021-12-13 21:01","market":"us","language":"en","title":"Toplines Before US Market Open on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1161576842","media":"Tiger Newspress","summary":"U.S. stock-index futures pointed to muted gains for major indexes ahead of a busy week of central-ba","content":"<p>U.S. stock-index futures pointed to muted gains for major indexes ahead of a busy week of central-bank decisions in major economies.</p>\n<p>At 8:00 a.m. ET, S&P 500 e-minis were up 11.25 points, or 0.24%, Nasdaq 100 e-minis were up 67 points, or 0.41%, and Dow e-minis were up 24 points, or 0.07%.<img src=\"https://static.tigerbbs.com/2db870f3d308c4d0618dd8c4333e65dd\" tg-width=\"1080\" tg-height=\"383\" referrerpolicy=\"no-referrer\">The key inflation reading came ahead of the Federal Reserve’s two-day policy meeting this week where the policymakers are expected to discuss speeding up the end of its bond-buying program.</p>\n<p>Fed Chair Jerome Powell, as well as a parade of Fed speakers, all recently suggested the central bank could end the $120 billion monthly bond purchase program sooner than the current timeline of June 2022.</p>\n<p>“We believe markets can continue to take a higher inflation reading in their stride, though additional volatility remains a risk. With Fed policy staying relatively accommodative, the backdrop for equities is still positive, and we favor winners from global growth,” said Mark Haefele, Chief Investment Officer of UBS Global Wealth Management.</p>\n<p>As of Sunday, the U.S. was approaching 800,000 coronavirus-related deaths. The new variant has pushed some government officials to reinstate health restrictions to slow the spread.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b><a href=\"https://laohu8.com/S/HOG\">Harley-Davidson</a></b>– The motorcycle maker’s stock surged 11.7% in the premarket after it announced that it is merging its “Livewire” electric motorcycle unit with a special purpose acquisition company. Livewire will have an enterprise value of about $1.8 billion and will trade on the New York Stock Exchange under the ticker symbol “LVW.”</p>\n<p><b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> </b>– <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> rose 1.4% in the premarket while <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> jumped 4.4% after a new Israeli study showed that a booster shot from their Covid-19 vaccine provided strong protection against severe illness from the omicron variant. <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>’s pre-market gains were trimmed following news of its deal to acquire Arena Pharmaceuticals.</p>\n<p><b><a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals</a> </b>– The drugmaker agreed to be acquired by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> for $100 per share in cash, or about $6.7 billion. Arena soared 93.1% in premarket trading following news of the transaction.</p>\n<p><b><a href=\"https://laohu8.com/S/PTON\">Peloton Interactive, Inc.</a></b> – The fitness equipment maker rebounded 2.6% in premarket action after falling 7% over the past three sessions. Pelotonreleased an ad featuring actor Chris Noth promoting the value of the company’s equipment, after his character’s death in the “Sex and the City” reboot following a Peloton ride.</p>\n<p><b><a href=\"https://laohu8.com/S/DLTR\">Dollar Tree</a> </b>– The discount retailer’s stock fell 1% in premarket trading after activist investor Mantle Ridge announced its intention to try to replace the entire Dollar Tree board. Dollar Tree called the move “unwarrantedly aggressive” and said it had offered to explore a settlement with Mantle Ridge, which owns 5.7% of Dollar Tree.</p>\n<p><b><a href=\"https://laohu8.com/S/AAPL\">Apple</a> </b>– <a href=\"https://laohu8.com/S/AAPL\">Apple</a> rose 1.1% in the premarket after J.P. Morgan Securities raised its price target for the stock to a Street-high of $210 per share from $180 a share, and reiterated it as a top pick going into 2022.</p>\n<p>Nasdaq-100 additions – Stocks being added to the index as of Monday, December 20, rose in premarket trading following news of their inclusion. The stocks include <b><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a></b>, up 2.7%;<b><a href=\"https://laohu8.com/S/ABNB\">Airbnb, Inc.</a></b> , up 2.1%;<b><a href=\"https://laohu8.com/S/FTNT\">Fortinet</a></b> , up 3.7%;<b><a href=\"https://laohu8.com/S/LCID\">Lucid Group Inc</a></b>, up 5.9%;<b><a href=\"https://laohu8.com/S/ZS\">Zscaler Inc.</a></b>, up 3.4%; and <b><a href=\"https://laohu8.com/S/DDOG\">Datadog</a></b>, up 3.1%.</p>\n<p>Nasdaq-100 subtractions – Stocks being replaced in the Nasdaq-100 include <b><a href=\"https://laohu8.com/S/CDW\">CDW Corp</a></b> , down 1.8% in the premarket;<b><a href=\"https://laohu8.com/S/FOXA\">Fox Corporation Class A</a></b> , down 2.2%;<b><a href=\"https://laohu8.com/S/CERN\">Cerner</a></b> , down 1.8%;<b><a href=\"https://laohu8.com/S/CHKP\">Check Point</a></b> , down 1.1%;<b><a href=\"https://laohu8.com/S/TCOM\">Trip.com Group Limited</a></b> , down 1.2%; and <b><a href=\"https://laohu8.com/S/INCY\">Incyte</a></b>, down 0.6%.</p>\n<p><b><a href=\"https://laohu8.com/S/RIVN\">Rivian Automotive, Inc.</a></b> – The electric vehicle maker’s stock rose 1.9% in the premarket following news that its R1T had been named Motor Trend’s truck of the year, beating out entries from Ford, GM and Hyundai.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-13 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock-index futures pointed to muted gains for major indexes ahead of a busy week of central-bank decisions in major economies.</p>\n<p>At 8:00 a.m. ET, S&P 500 e-minis were up 11.25 points, or 0.24%, Nasdaq 100 e-minis were up 67 points, or 0.41%, and Dow e-minis were up 24 points, or 0.07%.<img src=\"https://static.tigerbbs.com/2db870f3d308c4d0618dd8c4333e65dd\" tg-width=\"1080\" tg-height=\"383\" referrerpolicy=\"no-referrer\">The key inflation reading came ahead of the Federal Reserve’s two-day policy meeting this week where the policymakers are expected to discuss speeding up the end of its bond-buying program.</p>\n<p>Fed Chair Jerome Powell, as well as a parade of Fed speakers, all recently suggested the central bank could end the $120 billion monthly bond purchase program sooner than the current timeline of June 2022.</p>\n<p>“We believe markets can continue to take a higher inflation reading in their stride, though additional volatility remains a risk. With Fed policy staying relatively accommodative, the backdrop for equities is still positive, and we favor winners from global growth,” said Mark Haefele, Chief Investment Officer of UBS Global Wealth Management.</p>\n<p>As of Sunday, the U.S. was approaching 800,000 coronavirus-related deaths. The new variant has pushed some government officials to reinstate health restrictions to slow the spread.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b><a href=\"https://laohu8.com/S/HOG\">Harley-Davidson</a></b>– The motorcycle maker’s stock surged 11.7% in the premarket after it announced that it is merging its “Livewire” electric motorcycle unit with a special purpose acquisition company. Livewire will have an enterprise value of about $1.8 billion and will trade on the New York Stock Exchange under the ticker symbol “LVW.”</p>\n<p><b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> </b>– <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> rose 1.4% in the premarket while <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> jumped 4.4% after a new Israeli study showed that a booster shot from their Covid-19 vaccine provided strong protection against severe illness from the omicron variant. <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>’s pre-market gains were trimmed following news of its deal to acquire Arena Pharmaceuticals.</p>\n<p><b><a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals</a> </b>– The drugmaker agreed to be acquired by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> for $100 per share in cash, or about $6.7 billion. Arena soared 93.1% in premarket trading following news of the transaction.</p>\n<p><b><a href=\"https://laohu8.com/S/PTON\">Peloton Interactive, Inc.</a></b> – The fitness equipment maker rebounded 2.6% in premarket action after falling 7% over the past three sessions. Pelotonreleased an ad featuring actor Chris Noth promoting the value of the company’s equipment, after his character’s death in the “Sex and the City” reboot following a Peloton ride.</p>\n<p><b><a href=\"https://laohu8.com/S/DLTR\">Dollar Tree</a> </b>– The discount retailer’s stock fell 1% in premarket trading after activist investor Mantle Ridge announced its intention to try to replace the entire Dollar Tree board. Dollar Tree called the move “unwarrantedly aggressive” and said it had offered to explore a settlement with Mantle Ridge, which owns 5.7% of Dollar Tree.</p>\n<p><b><a href=\"https://laohu8.com/S/AAPL\">Apple</a> </b>– <a href=\"https://laohu8.com/S/AAPL\">Apple</a> rose 1.1% in the premarket after J.P. Morgan Securities raised its price target for the stock to a Street-high of $210 per share from $180 a share, and reiterated it as a top pick going into 2022.</p>\n<p>Nasdaq-100 additions – Stocks being added to the index as of Monday, December 20, rose in premarket trading following news of their inclusion. The stocks include <b><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a></b>, up 2.7%;<b><a href=\"https://laohu8.com/S/ABNB\">Airbnb, Inc.</a></b> , up 2.1%;<b><a href=\"https://laohu8.com/S/FTNT\">Fortinet</a></b> , up 3.7%;<b><a href=\"https://laohu8.com/S/LCID\">Lucid Group Inc</a></b>, up 5.9%;<b><a href=\"https://laohu8.com/S/ZS\">Zscaler Inc.</a></b>, up 3.4%; and <b><a href=\"https://laohu8.com/S/DDOG\">Datadog</a></b>, up 3.1%.</p>\n<p>Nasdaq-100 subtractions – Stocks being replaced in the Nasdaq-100 include <b><a href=\"https://laohu8.com/S/CDW\">CDW Corp</a></b> , down 1.8% in the premarket;<b><a href=\"https://laohu8.com/S/FOXA\">Fox Corporation Class A</a></b> , down 2.2%;<b><a href=\"https://laohu8.com/S/CERN\">Cerner</a></b> , down 1.8%;<b><a href=\"https://laohu8.com/S/CHKP\">Check Point</a></b> , down 1.1%;<b><a href=\"https://laohu8.com/S/TCOM\">Trip.com Group Limited</a></b> , down 1.2%; and <b><a href=\"https://laohu8.com/S/INCY\">Incyte</a></b>, down 0.6%.</p>\n<p><b><a href=\"https://laohu8.com/S/RIVN\">Rivian Automotive, Inc.</a></b> – The electric vehicle maker’s stock rose 1.9% in the premarket following news that its R1T had been named Motor Trend’s truck of the year, beating out entries from Ford, GM and Hyundai.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INCY":"因塞特医疗","ABNB":"爱彼迎","PFE":"辉瑞","FOXA":"福克斯-A","CHKP":"Check Point软件科技","TCOM":"携程网","HOG":"哈雷戴维森","LCID":"Lucid Group Inc","FTNT":"飞塔信息","CERN":"美国塞纳","DDOG":"Datadog",".DJI":"道琼斯","RIVN":"Rivian Automotive, Inc.","ZS":"Zscaler Inc.",".IXIC":"NASDAQ Composite","AAPL":"苹果","PANW":"Palo Alto Networks",".SPX":"S&P 500 Index","ARNA":"阿里那","BNTX":"BioNTech SE","CDW":"CDW Corporation","PTON":"Peloton Interactive, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161576842","content_text":"U.S. stock-index futures pointed to muted gains for major indexes ahead of a busy week of central-bank decisions in major economies.\nAt 8:00 a.m. ET, S&P 500 e-minis were up 11.25 points, or 0.24%, Nasdaq 100 e-minis were up 67 points, or 0.41%, and Dow e-minis were up 24 points, or 0.07%.The key inflation reading came ahead of the Federal Reserve’s two-day policy meeting this week where the policymakers are expected to discuss speeding up the end of its bond-buying program.\nFed Chair Jerome Powell, as well as a parade of Fed speakers, all recently suggested the central bank could end the $120 billion monthly bond purchase program sooner than the current timeline of June 2022.\n“We believe markets can continue to take a higher inflation reading in their stride, though additional volatility remains a risk. With Fed policy staying relatively accommodative, the backdrop for equities is still positive, and we favor winners from global growth,” said Mark Haefele, Chief Investment Officer of UBS Global Wealth Management.\nAs of Sunday, the U.S. was approaching 800,000 coronavirus-related deaths. The new variant has pushed some government officials to reinstate health restrictions to slow the spread.\nStocks making the biggest moves premarket: \nHarley-Davidson– The motorcycle maker’s stock surged 11.7% in the premarket after it announced that it is merging its “Livewire” electric motorcycle unit with a special purpose acquisition company. Livewire will have an enterprise value of about $1.8 billion and will trade on the New York Stock Exchange under the ticker symbol “LVW.”\nPfizer,BioNTech SE – Pfizer rose 1.4% in the premarket while BioNTech SE jumped 4.4% after a new Israeli study showed that a booster shot from their Covid-19 vaccine provided strong protection against severe illness from the omicron variant. Pfizer’s pre-market gains were trimmed following news of its deal to acquire Arena Pharmaceuticals.\nArena Pharmaceuticals – The drugmaker agreed to be acquired by Pfizer for $100 per share in cash, or about $6.7 billion. Arena soared 93.1% in premarket trading following news of the transaction.\nPeloton Interactive, Inc. – The fitness equipment maker rebounded 2.6% in premarket action after falling 7% over the past three sessions. Pelotonreleased an ad featuring actor Chris Noth promoting the value of the company’s equipment, after his character’s death in the “Sex and the City” reboot following a Peloton ride.\nDollar Tree – The discount retailer’s stock fell 1% in premarket trading after activist investor Mantle Ridge announced its intention to try to replace the entire Dollar Tree board. Dollar Tree called the move “unwarrantedly aggressive” and said it had offered to explore a settlement with Mantle Ridge, which owns 5.7% of Dollar Tree.\nApple – Apple rose 1.1% in the premarket after J.P. Morgan Securities raised its price target for the stock to a Street-high of $210 per share from $180 a share, and reiterated it as a top pick going into 2022.\nNasdaq-100 additions – Stocks being added to the index as of Monday, December 20, rose in premarket trading following news of their inclusion. The stocks include Palo Alto Networks, up 2.7%;Airbnb, Inc. , up 2.1%;Fortinet , up 3.7%;Lucid Group Inc, up 5.9%;Zscaler Inc., up 3.4%; and Datadog, up 3.1%.\nNasdaq-100 subtractions – Stocks being replaced in the Nasdaq-100 include CDW Corp , down 1.8% in the premarket;Fox Corporation Class A , down 2.2%;Cerner , down 1.8%;Check Point , down 1.1%;Trip.com Group Limited , down 1.2%; and Incyte, down 0.6%.\nRivian Automotive, Inc. – The electric vehicle maker’s stock rose 1.9% in the premarket following news that its R1T had been named Motor Trend’s truck of the year, beating out entries from Ford, GM and Hyundai.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"AAPL":0.9,"ABNB":0.9,"ARNA":0.9,"BNTX":0.9,"CDW":0.9,"CERN":0.9,"CHKP":0.9,"DDOG":0.9,"FOXA":0.9,"FTNT":0.9,"HOG":0.9,"INCY":0.9,"LCID":0.9,"PANW":0.9,"PFE":0.9,"PTON":0.9,"RIVN":0.9,"TCOM":0.9,"ZS":0.9}},"isVote":1,"tweetType":1,"viewCount":1540,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604968891,"gmtCreate":1639312960511,"gmtModify":1639313184310,"author":{"id":"3586429646894350","authorId":"3586429646894350","name":"IcyAlchemist","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586429646894350","idStr":"3586429646894350"},"themes":[],"htmlText":"Like and comment ","listText":"Like and comment ","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604968891","repostId":"2190719916","repostType":4,"repost":{"id":"2190719916","kind":"highlight","pubTimestamp":1639280175,"share":"https://ttm.financial/m/news/2190719916?lang=&edition=full","pubTime":"2021-12-12 11:36","market":"us","language":"en","title":"Is Inflation Going to Cool Down Anytime Soon?","url":"https://stock-news.laohu8.com/highlight/detail?id=2190719916","media":"Motley Fool","summary":"Two Motley Fool contributors discuss the issue weighing on a lot of people's minds.","content":"<p>Investors and the general public as a whole are worried about the surging rate of inflation, and these concerns continue to drive some of the volatility we're seeing in the broader market. In this segment of<i> Backstage Pass</i>, recorded on <b>Nov. 10</b>, Fool contributors Connor Allen and Rachel Warren discuss inflation and investing in this challenging market environment.</p>\n<p><b>Connor Allen</b>: But to go back to the original question about transitory inflation, I think most people have hopped off that bus by now. I think right when this started, a lot of people were on the transitory bus. They thought a lot of the bottlenecks and the supply chain issues that were being caused we're going to get solved and basically deflation will come and replace that and prices would go back to normal. I don't think a lot of people think that anymore.</p>\n<p>Because when you think about a company that's selling a product, and they realize that the market will pay $5 for something that used to be $3 and are they ever going to bring it back to $3? I don't think so. I think that's hard to make companies do, especially when there's such a variety of costs across all industries and all companies. You don't know what costs are going to come down when.</p>\n<p>Gas is <a href=\"https://laohu8.com/S/AONE.U\">one</a> that's a major issue. I think that probably is the number one issue for a lot of increasing costs for companies because everything's delivered, whether it's delivered to a warehouse like <b>Amazon</b>, whether it's delivered to a retail store like <b>Macy's</b>, or whether it's delivered to your home. There's a lot of different things and the cost obviously of gas being I think it's around a national averaged around $3.20 I believe.</p>\n<p>That's a cost that you can't get around, and you can't really innovate around those gas prices. Obviously, electric vehicles could potentially be that fix, but those costs are going up as well. [laughs] There's some projections that I was reading about how the national average of gas prices could be around $5 a gallon by the end of the year.</p>\n<p>That could be really painful, not only on my wallet, but [laughs] not on a lot of Americans' wallets. Hopefully we can get that down. But to be honest with you, I'm expecting long-term inflation. I'm not expecting this to be a transitory thing.</p>\n<p><b>Rachel Warren:</b> I agree with you Connor and unfortunately, I don't really see this inflation just dying down overnight or going anywhere anytime soon. I think it's going to be much more of a gradual recovery and perhaps in some cases like what you were saying, we're going to see permanent pricing increases in some of these consumer good categories.</p>\n<p>I think it's something that businesses and consumers are going to have to contend with for a long time. I think people are adjusting to these changes hard as they are. I think it's also helpful to remember this isn't just a U.S. issue. This is a global problem for companies and consumers.</p>\n<p>I saw this interesting article on <i>CNBC</i> today and the Chief Financial Officer of a large Belgian Dutch grocer called <b>Ahold Delhaize</b> was talking about how the company is dealing with the supply chain bottlenecks that are also having this impact on inflation and everything else and she said, \"I think what we're definitely seeing is inflation is picking up. But what I would also say is that when you look at food at the smaller share of the wallet in some other categories.\"</p>\n<p>Another thing was, a lot of these companies are saying this is something we are going to be seeing for quite a long time. The CEO of <b>Siemens</b> <b>Energy</b> told <i>CNBC</i>, the industrial world is going to be dealing with the supply chain bottleneck issues for a long time, which is also driving these other inflation problems. I don't think it's something that's going anywhere, anytime soon.</p>\n<p>As a consumer, it's obviously not fun to see. I think it's something to be patient with and deal with as it comes. But jumping off of what Taylor was saying in terms of staying invested in the stock market, but maybe you do adjust the type of stocks that you buy during these times and sometimes especially during bumpy periods in the market, it can be a good time to look at your portfolio and see maybe it needs some rebalancing.</p>\n<p>Maybe the balance of stocks that are more prone to headwinds during these bumpy times could use some balancing with more stalwart stocks that aren't necessarily as prone to these inflationary pressures. I think even amid rising prices and high inflation, you think of companies like Amazon that reported impacted earnings due to related supply chain constraints. The market still managed to deliver record highs.</p>\n<p>Recently over the last few weeks we had that happen a couple of times. Try not to focus too much on one day in the stock market. When you look at the market performance over the long term, investors who they'd invested in the market has generated pretty great portfolio returns. I'm personally not changing the way I'm investing right now, but I may change some of the type of stocks I buy in the coming months for sure.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Inflation Going to Cool Down Anytime Soon?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Inflation Going to Cool Down Anytime Soon?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-12 11:36 GMT+8 <a href=https://www.fool.com/investing/2021/12/11/is-inflation-going-to-cool-down-anytime-soon/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors and the general public as a whole are worried about the surging rate of inflation, and these concerns continue to drive some of the volatility we're seeing in the broader market. In this ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/11/is-inflation-going-to-cool-down-anytime-soon/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/12/11/is-inflation-going-to-cool-down-anytime-soon/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190719916","content_text":"Investors and the general public as a whole are worried about the surging rate of inflation, and these concerns continue to drive some of the volatility we're seeing in the broader market. In this segment of Backstage Pass, recorded on Nov. 10, Fool contributors Connor Allen and Rachel Warren discuss inflation and investing in this challenging market environment.\nConnor Allen: But to go back to the original question about transitory inflation, I think most people have hopped off that bus by now. I think right when this started, a lot of people were on the transitory bus. They thought a lot of the bottlenecks and the supply chain issues that were being caused we're going to get solved and basically deflation will come and replace that and prices would go back to normal. I don't think a lot of people think that anymore.\nBecause when you think about a company that's selling a product, and they realize that the market will pay $5 for something that used to be $3 and are they ever going to bring it back to $3? I don't think so. I think that's hard to make companies do, especially when there's such a variety of costs across all industries and all companies. You don't know what costs are going to come down when.\nGas is one that's a major issue. I think that probably is the number one issue for a lot of increasing costs for companies because everything's delivered, whether it's delivered to a warehouse like Amazon, whether it's delivered to a retail store like Macy's, or whether it's delivered to your home. There's a lot of different things and the cost obviously of gas being I think it's around a national averaged around $3.20 I believe.\nThat's a cost that you can't get around, and you can't really innovate around those gas prices. Obviously, electric vehicles could potentially be that fix, but those costs are going up as well. [laughs] There's some projections that I was reading about how the national average of gas prices could be around $5 a gallon by the end of the year.\nThat could be really painful, not only on my wallet, but [laughs] not on a lot of Americans' wallets. Hopefully we can get that down. But to be honest with you, I'm expecting long-term inflation. I'm not expecting this to be a transitory thing.\nRachel Warren: I agree with you Connor and unfortunately, I don't really see this inflation just dying down overnight or going anywhere anytime soon. I think it's going to be much more of a gradual recovery and perhaps in some cases like what you were saying, we're going to see permanent pricing increases in some of these consumer good categories.\nI think it's something that businesses and consumers are going to have to contend with for a long time. I think people are adjusting to these changes hard as they are. I think it's also helpful to remember this isn't just a U.S. issue. This is a global problem for companies and consumers.\nI saw this interesting article on CNBC today and the Chief Financial Officer of a large Belgian Dutch grocer called Ahold Delhaize was talking about how the company is dealing with the supply chain bottlenecks that are also having this impact on inflation and everything else and she said, \"I think what we're definitely seeing is inflation is picking up. But what I would also say is that when you look at food at the smaller share of the wallet in some other categories.\"\nAnother thing was, a lot of these companies are saying this is something we are going to be seeing for quite a long time. The CEO of Siemens Energy told CNBC, the industrial world is going to be dealing with the supply chain bottleneck issues for a long time, which is also driving these other inflation problems. I don't think it's something that's going anywhere, anytime soon.\nAs a consumer, it's obviously not fun to see. I think it's something to be patient with and deal with as it comes. But jumping off of what Taylor was saying in terms of staying invested in the stock market, but maybe you do adjust the type of stocks that you buy during these times and sometimes especially during bumpy periods in the market, it can be a good time to look at your portfolio and see maybe it needs some rebalancing.\nMaybe the balance of stocks that are more prone to headwinds during these bumpy times could use some balancing with more stalwart stocks that aren't necessarily as prone to these inflationary pressures. I think even amid rising prices and high inflation, you think of companies like Amazon that reported impacted earnings due to related supply chain constraints. The market still managed to deliver record highs.\nRecently over the last few weeks we had that happen a couple of times. Try not to focus too much on one day in the stock market. When you look at the market performance over the long term, investors who they'd invested in the market has generated pretty great portfolio returns. I'm personally not changing the way I'm investing right now, but I may change some of the type of stocks I buy in the coming months for sure.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":3121,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604968919,"gmtCreate":1639312887026,"gmtModify":1639312921841,"author":{"id":"3586429646894350","authorId":"3586429646894350","name":"IcyAlchemist","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586429646894350","idStr":"3586429646894350"},"themes":[],"htmlText":"Like and comment ","listText":"Like and comment ","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604968919","repostId":"1103250344","repostType":4,"repost":{"id":"1103250344","kind":"news","pubTimestamp":1639280672,"share":"https://ttm.financial/m/news/1103250344?lang=&edition=full","pubTime":"2021-12-12 11:44","market":"us","language":"en","title":"US IPO Week Ahead: IoT solutions, wine, and satellites in a 3 IPO week","url":"https://stock-news.laohu8.com/highlight/detail?id=1103250344","media":"renaissancecap...","summary":"The IPO market is expected to stay relatively quiet in the week ahead with three IPOs scheduled to r","content":"<p>The IPO market is expected to stay relatively quiet in the week ahead with three IPOs scheduled to raise $789 million.</p>\n<p>IoT solutions developer<b>Samsara</b>(IOT) plans to raise $753 million at an $11.6 billion market cap. This \"internet-of-things\" company provides a cloud-based platform that connects the assets of businesses with physical operations, enhancing operational efficiency and asset and employee productivity. Fast growing but highly unprofitable, Samsara saw double-digit growth for customers with $100k+ ARR in the 9mo FY22.</p>\n<p>Wine brand<b>Fresh Vine Wine</b>(VINE) plans to raise $21 million at a $116 million market cap. This celebrity-founded company produces low carb, low calorie premium wines. Growing but highly unprofitable, Fresh Vine sells its wines through wholesale, retail, and DTC channels, and is able to conduct wholesale distribution in all 50 states and Puerto Rico.</p>\n<p>Micro-cap satellite developer<b>Sidus Space</b>(SIDU) plans to raise $15 million at an $81 million market cap. This company provides commercial satellite services such as design, manufacture, launch, and data collection. Sidus Space has generated space-related manufacturing revenues to date, but is highly unprofitable with negative gross margin in the 9mo21.</p>\n<p><img src=\"https://static.tigerbbs.com/ead80e54642569e2b7b368c8d50dc265\" tg-width=\"1409\" tg-height=\"457\" referrerpolicy=\"no-referrer\"></p>","source":"lsy1619493174116","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: IoT solutions, wine, and satellites in a 3 IPO week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: IoT solutions, wine, and satellites in a 3 IPO week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-12 11:44 GMT+8 <a href=https://www.renaissancecapital.com/IPO-Center/News/89474/US-IPO-Week-Ahead-IoT-solutions-wine-and-satellites-in-a-3-IPO-week><strong>renaissancecap...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is expected to stay relatively quiet in the week ahead with three IPOs scheduled to raise $789 million.\nIoT solutions developerSamsara(IOT) plans to raise $753 million at an $11.6 ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/89474/US-IPO-Week-Ahead-IoT-solutions-wine-and-satellites-in-a-3-IPO-week\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SIDU":"Sidus Space Inc.","IOT":"Samsara, Inc.",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/89474/US-IPO-Week-Ahead-IoT-solutions-wine-and-satellites-in-a-3-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103250344","content_text":"The IPO market is expected to stay relatively quiet in the week ahead with three IPOs scheduled to raise $789 million.\nIoT solutions developerSamsara(IOT) plans to raise $753 million at an $11.6 billion market cap. This \"internet-of-things\" company provides a cloud-based platform that connects the assets of businesses with physical operations, enhancing operational efficiency and asset and employee productivity. Fast growing but highly unprofitable, Samsara saw double-digit growth for customers with $100k+ ARR in the 9mo FY22.\nWine brandFresh Vine Wine(VINE) plans to raise $21 million at a $116 million market cap. This celebrity-founded company produces low carb, low calorie premium wines. Growing but highly unprofitable, Fresh Vine sells its wines through wholesale, retail, and DTC channels, and is able to conduct wholesale distribution in all 50 states and Puerto Rico.\nMicro-cap satellite developerSidus Space(SIDU) plans to raise $15 million at an $81 million market cap. This company provides commercial satellite services such as design, manufacture, launch, and data collection. Sidus Space has generated space-related manufacturing revenues to date, but is highly unprofitable with negative gross margin in the 9mo21.","news_type":1,"symbols_score_info":{".DJI":0,".IXIC":0,".SPX":0,"IOT":0,"SIDU":0,"VINE":0}},"isVote":1,"tweetType":1,"viewCount":2543,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602719340,"gmtCreate":1639065421675,"gmtModify":1639066018747,"author":{"id":"3586429646894350","authorId":"3586429646894350","name":"IcyAlchemist","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586429646894350","idStr":"3586429646894350"},"themes":[],"htmlText":"Like and comment ","listText":"Like and comment ","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/602719340","repostId":"2190617302","repostType":4,"repost":{"id":"2190617302","kind":"highlight","pubTimestamp":1639063118,"share":"https://ttm.financial/m/news/2190617302?lang=&edition=full","pubTime":"2021-12-09 23:18","market":"us","language":"en","title":"2 Short-Squeeze Candidates That Could Go Parabolic Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=2190617302","media":"Motley Fool","summary":"Cortexyme and Heron Therapeutics are two of the most heavily shorted biopharma stocks right now.","content":"<p>Short squeezes can deliver enormous returns for investors in the blink of an eye. Several so-called \"meme stocks\" generated jaw-dropping gains for investors earlier this year due to this phenomenon.</p>\n<p>The mechanics of a short squeeze are fairly straightforward. Short-sellers, or investors betting against an equity, are essentially forced to cover their position in response to an uptick in investors buying the stock. The net result, more often than not, is a brief, parabolic-like move higher in the stock in question.</p>\n<p>Last month, short-sellers seemingly took advantage of the widespread weakness across the biopharma space. As a result, scores of biopharma equities sport sizable short positions as a percentage of the outstanding shares. The Alzheimer's specialist <b>Cortexyme</b> (NASDAQ:CRTX) and the commercial-stage biotech <b>Heron Therapeutics</b> (NASDAQ:HRTX) were two of the most heavily shorted pharma stocks at last count. These two drugmakers, however, could prove to be terrible stocks to bet against. Here's why.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b6841093892c649c73d00f9f0f9f2663\" tg-width=\"700\" tg-height=\"533\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Cortexyme: Alzheimer's drugs are too risky to short</h2>\n<p>Cortexyme, a small-molecule drug developer, became a huge target for short-sellers after its experimental Alzheimer's disease treatment atuzaginstat flopped in a late-stage trial toward the end of October. In fact, the biotech's shares were <i>the</i> most heavily shorted equity among biopharmas at last count, a little over two weeks ago. Short-sellers are clearly betting that atuzaginstat is basically dead on arrival. That rather dire take might not be the case, however.</p>\n<p>During a recent conference call, Cortexyme management said that the drug does appear to show a worthwhile clinical benefit for Alzheimer's patients who also tested positive for the gum-disease bacteria Porphyromonas gingivalis. While this analysis is far from definitive, it may help the company identify the correct patient population to evaluate atuzaginstat in, via another late-stage trial. Cortexyme intends to do just that. Almost immediately after the drug disappointed in this all-comer study, management announced plans to target a more-focused group of patients in another pivotal study.</p>\n<p>Why is Cortexyme an outstanding short-squeeze candidate? Even as a drug exclusively for Alzheimer's disease patients with an active P. gingivalis infection, it should still generate mega-blockbuster sales (greater than $5 billion). That's a massive revenue stream for a company with a $420 million market cap at present. Cortexyme plans to provide an update to investors on this upcoming clinical trial in the first quarter of 2022. This update could very well spark a short squeeze in the biotech's stock.</p>\n<h2>Heron Therapeutics: Down but not out</h2>\n<p>Heron Therapeutics has been a top short-seller target for well over a year now. As a result, the biotech's stock is currently <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most heavily shorted within its immediate peer group. Bears have bet against this small-cap pharma stock for two clear reasons. First, Heron's chemotherapy-induced nausea and vomiting franchise has underwhelmed from a commercial standpoint.</p>\n<p>Second, the biotech's highly anticipated acute pain medication Zynrelef didn't get the type of broad label from the Food and Drug Administration (FDA) that would have allowed it to become a major growth driver right off the bat. Heron is working with the FDA to expand Zynrelef's label, but this process will take a while to work through.</p>\n<p>The good news is that Zynrelef still holds the potential to rake in upward of $500 million in sales by the middle of the decade. That's a nice chunk of change for a biotech with a sub-$1 billion market cap.</p>\n<p>Why might Heron be gearing up for a noteworthy short squeeze? It is expected to announce important commercial and regulatory updates for Zynrelef before the end of February 2022. If the drug's commercial launch continues to show promise and its label-expansion plans remain on track, the stock should reverse course. The biotech's shares, after all, are currently trading at under 3 times 2023 sales, which is a dirt cheap valuation for a commercial-stage biotech.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Short-Squeeze Candidates That Could Go Parabolic Soon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Short-Squeeze Candidates That Could Go Parabolic Soon\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-09 23:18 GMT+8 <a href=https://www.fool.com/investing/2021/12/09/2-short-squeeze-stock-candidates-that-could-go-par/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Short squeezes can deliver enormous returns for investors in the blink of an eye. Several so-called \"meme stocks\" generated jaw-dropping gains for investors earlier this year due to this phenomenon.\n...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/09/2-short-squeeze-stock-candidates-that-could-go-par/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HRTX":"Heron Therapeutics Inc.","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2021/12/09/2-short-squeeze-stock-candidates-that-could-go-par/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190617302","content_text":"Short squeezes can deliver enormous returns for investors in the blink of an eye. Several so-called \"meme stocks\" generated jaw-dropping gains for investors earlier this year due to this phenomenon.\nThe mechanics of a short squeeze are fairly straightforward. Short-sellers, or investors betting against an equity, are essentially forced to cover their position in response to an uptick in investors buying the stock. The net result, more often than not, is a brief, parabolic-like move higher in the stock in question.\nLast month, short-sellers seemingly took advantage of the widespread weakness across the biopharma space. As a result, scores of biopharma equities sport sizable short positions as a percentage of the outstanding shares. The Alzheimer's specialist Cortexyme (NASDAQ:CRTX) and the commercial-stage biotech Heron Therapeutics (NASDAQ:HRTX) were two of the most heavily shorted pharma stocks at last count. These two drugmakers, however, could prove to be terrible stocks to bet against. Here's why.\nImage source: Getty Images.\nCortexyme: Alzheimer's drugs are too risky to short\nCortexyme, a small-molecule drug developer, became a huge target for short-sellers after its experimental Alzheimer's disease treatment atuzaginstat flopped in a late-stage trial toward the end of October. In fact, the biotech's shares were the most heavily shorted equity among biopharmas at last count, a little over two weeks ago. Short-sellers are clearly betting that atuzaginstat is basically dead on arrival. That rather dire take might not be the case, however.\nDuring a recent conference call, Cortexyme management said that the drug does appear to show a worthwhile clinical benefit for Alzheimer's patients who also tested positive for the gum-disease bacteria Porphyromonas gingivalis. While this analysis is far from definitive, it may help the company identify the correct patient population to evaluate atuzaginstat in, via another late-stage trial. Cortexyme intends to do just that. Almost immediately after the drug disappointed in this all-comer study, management announced plans to target a more-focused group of patients in another pivotal study.\nWhy is Cortexyme an outstanding short-squeeze candidate? Even as a drug exclusively for Alzheimer's disease patients with an active P. gingivalis infection, it should still generate mega-blockbuster sales (greater than $5 billion). That's a massive revenue stream for a company with a $420 million market cap at present. Cortexyme plans to provide an update to investors on this upcoming clinical trial in the first quarter of 2022. This update could very well spark a short squeeze in the biotech's stock.\nHeron Therapeutics: Down but not out\nHeron Therapeutics has been a top short-seller target for well over a year now. As a result, the biotech's stock is currently one of the most heavily shorted within its immediate peer group. Bears have bet against this small-cap pharma stock for two clear reasons. First, Heron's chemotherapy-induced nausea and vomiting franchise has underwhelmed from a commercial standpoint.\nSecond, the biotech's highly anticipated acute pain medication Zynrelef didn't get the type of broad label from the Food and Drug Administration (FDA) that would have allowed it to become a major growth driver right off the bat. Heron is working with the FDA to expand Zynrelef's label, but this process will take a while to work through.\nThe good news is that Zynrelef still holds the potential to rake in upward of $500 million in sales by the middle of the decade. That's a nice chunk of change for a biotech with a sub-$1 billion market cap.\nWhy might Heron be gearing up for a noteworthy short squeeze? It is expected to announce important commercial and regulatory updates for Zynrelef before the end of February 2022. If the drug's commercial launch continues to show promise and its label-expansion plans remain on track, the stock should reverse course. The biotech's shares, after all, are currently trading at under 3 times 2023 sales, which is a dirt cheap valuation for a commercial-stage biotech.","news_type":1,"symbols_score_info":{"CRTX":0.9,"HRTX":0.9}},"isVote":1,"tweetType":1,"viewCount":2291,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602710172,"gmtCreate":1639065290056,"gmtModify":1639065969239,"author":{"id":"3586429646894350","authorId":"3586429646894350","name":"IcyAlchemist","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586429646894350","idStr":"3586429646894350"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/602710172","repostId":"1134628800","repostType":4,"repost":{"id":"1134628800","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1639064594,"share":"https://ttm.financial/m/news/1134628800?lang=&edition=full","pubTime":"2021-12-09 23:43","market":"us","language":"en","title":"10 Biggest Price Target Changes For Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1134628800","media":"Benzinga","summary":"SVB Leerink boosted the price target on Edwards Lifesciences Corporation from $130 to $135. Edwards ","content":"<ul>\n <li>SVB Leerink boosted the price target on <b>Edwards Lifesciences Corporation</b> from $130 to $135. Edwards Lifesciences shares rose 1% to trade at $120.68 on Thursday.</li>\n <li>Keybanc raised <b>The Sherwin-Williams Company</b> price target from $350 to $384. Sherwin-Williams shares rose 1% to $345.68 on Thursday.</li>\n <li>Piper Sandler cut <b>Udemy, Inc.</b> price target from $37 to $34. Udemy shares fell 2% to trade at $20.65 on Thursday.</li>\n <li>Needham lowered the price target on <b>Esperion Therapeutics, Inc.</b> from $20 to $12. Esperion Therapeutics shares dropped 9% to $5.34 on Thursday.</li>\n <li>JP Morgan lifted <b>Phillips 66</b> price target from $83 to $93. Phillips 66 shares rose 0.7% to $72.36 on Thursday.</li>\n <li>RBC Capital cut the price target for <b>Cincinnati Financial Corporation</b> from $135 to $130. Cincinnati Financial shares fell 1.7% to $115.23 on Thursday.</li>\n <li>Chardan Capital raised <b>Dicerna Pharmaceuticals, Inc.</b> price target from $28 to $38.25. Dicerna Pharmaceuticals shares rose 0.1% to $38.03 on Thursday.</li>\n <li>Morgan Stanley boosted the price target on <b>Oshkosh Corporation</b> from $134 to $144. Oshkosh shares fell 1.4% to trade at $111.45 on Thursday.</li>\n <li>Wells Fargo cut the price target for <b>Dow Inc.</b> from $75 to $67. Dow shares fell 0.8% to $54.49 on Thursday.</li>\n <li>Barclays raised <b>McKesson Corporation</b> price target from $270 to $290. McKesson shares rose 1.1% to $229.33 on Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-09 23:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>SVB Leerink boosted the price target on <b>Edwards Lifesciences Corporation</b> from $130 to $135. Edwards Lifesciences shares rose 1% to trade at $120.68 on Thursday.</li>\n <li>Keybanc raised <b>The Sherwin-Williams Company</b> price target from $350 to $384. Sherwin-Williams shares rose 1% to $345.68 on Thursday.</li>\n <li>Piper Sandler cut <b>Udemy, Inc.</b> price target from $37 to $34. Udemy shares fell 2% to trade at $20.65 on Thursday.</li>\n <li>Needham lowered the price target on <b>Esperion Therapeutics, Inc.</b> from $20 to $12. Esperion Therapeutics shares dropped 9% to $5.34 on Thursday.</li>\n <li>JP Morgan lifted <b>Phillips 66</b> price target from $83 to $93. Phillips 66 shares rose 0.7% to $72.36 on Thursday.</li>\n <li>RBC Capital cut the price target for <b>Cincinnati Financial Corporation</b> from $135 to $130. Cincinnati Financial shares fell 1.7% to $115.23 on Thursday.</li>\n <li>Chardan Capital raised <b>Dicerna Pharmaceuticals, Inc.</b> price target from $28 to $38.25. Dicerna Pharmaceuticals shares rose 0.1% to $38.03 on Thursday.</li>\n <li>Morgan Stanley boosted the price target on <b>Oshkosh Corporation</b> from $134 to $144. Oshkosh shares fell 1.4% to trade at $111.45 on Thursday.</li>\n <li>Wells Fargo cut the price target for <b>Dow Inc.</b> from $75 to $67. Dow shares fell 0.8% to $54.49 on Thursday.</li>\n <li>Barclays raised <b>McKesson Corporation</b> price target from $270 to $290. McKesson shares rose 1.1% to $229.33 on Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OSK":"Oshkosh","DOW":"陶氏化学","ESPR":"Esperion Therapeutics Inc.","EW":"爱德华兹","SHW":"宣伟公司","CINF":"辛辛那提金融","UDMY":"Udemy, Inc.","DRNA":"Dicerna Pharmaceuticals, Inc.","MCK":"麦克森药物批发","PSX":"Phillips 66"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134628800","content_text":"SVB Leerink boosted the price target on Edwards Lifesciences Corporation from $130 to $135. Edwards Lifesciences shares rose 1% to trade at $120.68 on Thursday.\nKeybanc raised The Sherwin-Williams Company price target from $350 to $384. Sherwin-Williams shares rose 1% to $345.68 on Thursday.\nPiper Sandler cut Udemy, Inc. price target from $37 to $34. Udemy shares fell 2% to trade at $20.65 on Thursday.\nNeedham lowered the price target on Esperion Therapeutics, Inc. from $20 to $12. Esperion Therapeutics shares dropped 9% to $5.34 on Thursday.\nJP Morgan lifted Phillips 66 price target from $83 to $93. Phillips 66 shares rose 0.7% to $72.36 on Thursday.\nRBC Capital cut the price target for Cincinnati Financial Corporation from $135 to $130. Cincinnati Financial shares fell 1.7% to $115.23 on Thursday.\nChardan Capital raised Dicerna Pharmaceuticals, Inc. price target from $28 to $38.25. Dicerna Pharmaceuticals shares rose 0.1% to $38.03 on Thursday.\nMorgan Stanley boosted the price target on Oshkosh Corporation from $134 to $144. Oshkosh shares fell 1.4% to trade at $111.45 on Thursday.\nWells Fargo cut the price target for Dow Inc. from $75 to $67. Dow shares fell 0.8% to $54.49 on Thursday.\nBarclays raised McKesson Corporation price target from $270 to $290. McKesson shares rose 1.1% to $229.33 on Thursday.","news_type":1,"symbols_score_info":{"CINF":0.9,"DOW":0.9,"DRNA":0.9,"ESPR":0.9,"EW":0.9,"MCK":0.9,"OSK":0.9,"PSX":0.9,"SHW":0.9,"UDMY":0.9}},"isVote":1,"tweetType":1,"viewCount":1829,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602383179,"gmtCreate":1638972268751,"gmtModify":1638972269010,"author":{"id":"3586429646894350","authorId":"3586429646894350","name":"IcyAlchemist","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586429646894350","idStr":"3586429646894350"},"themes":[],"htmlText":"Really? ","listText":"Really? ","text":"Really?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/602383179","repostId":"1196974870","repostType":4,"repost":{"id":"1196974870","kind":"news","pubTimestamp":1638971896,"share":"https://ttm.financial/m/news/1196974870?lang=&edition=full","pubTime":"2021-12-08 21:58","market":"us","language":"en","title":"GameStop Stock Could Soar After Its Recent Plunge. Here's Why.","url":"https://stock-news.laohu8.com/highlight/detail?id=1196974870","media":"TheStreet","summary":"Down more than 25% since late November, here’s what could happen next for the original meme stock.\nA","content":"<p>Down more than 25% since late November, here’s what could happen next for the original meme stock.</p>\n<p>As seen in recent days, GameStop stock has been affected by the stock market’s latest round of volatility. Due to news of the Covid-19 Omicron variant, plus talk from the Federal Reserve about an end to its “easy money” policies, stocks across-the-board have declined since late November.</p>\n<p>During the same timeframe, shares in the video game retailer and “meme stock bluechip” have fallen by some 25%. But now, as Omicron worries may be fading, and volatility could soon clear up, what’s the next move for GameStop?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/795e002c4033cf494520d82da3291dd6\" tg-width=\"1240\" tg-height=\"698\" width=\"100%\" height=\"auto\"><span>Figure 1: GameStop store.</span></p>\n<p>Put simply, it’s debatable. Bulls can point to certain factors to support their views, as can bears. With this, let’s dive in, and explore what could push shares higher (or lower) from here.</p>\n<p><b>How GME Stock Could Rebound After The Omicron Selloff</b></p>\n<p>With its rapid drop during the week ending Dec 3, it may seem as if this stock is starting to lose its “unsinkable” reputation earned after holding onto most of its gains from its incredible run earlier this year.</p>\n<p>But while many in the so-called “Ape army” may have trimmed/exited positions last week, there could be something that stops this latest selloff from being the beginning of the end for GME stock.</p>\n<p>That would be the company’s upcoming earnings release on Dec 8. If coupled with a recovery from the Omicron selloff, shares could experience a big rebound in price.</p>\n<p>This may be especially true if, along with better-than-expected earnings, the company releases more details about its e-commerce plans, plus other initiatives, such as its rumored move into NFTs (non-fungible tokens). News like it could help convince “Apes” still long the stock to maintain their positions, and convince others who got out after last week’s volatility to dive back into it.</p>\n<p><b>Why The GameStop Price Collapse May Continue</b></p>\n<p>While it may be premature to say that many in the “Ape” community are ready to throw in the towel on GME stock, there is some evidence pointing in this direction.</p>\n<p>Chatter on Reddit’s various stock-trading subreddits is dropping once again. Although according to <i>ApeWisdom.io</i> mentions are up 47% in the last 24 hours, the current level of discussion about it on the platform is down considerably from the elevated levels seen last month.</p>\n<p>The main rationale behind holding this stock (to short-squeeze it) has fallen off as well. According to Fintel.io,short interest has dropped to just under 11%.</p>\n<p>GME’s waning appeal as a squeeze play may explain some of the frustration expressed by Reddit traders, after Fidelity Investments incorrectly stated the number of shares available to short through its platform.</p>\n<p><b>Bottom Line</b></p>\n<p>Bouncing between $160 and $170 per share today, it’s not definitive as to where GME stock is headed from here.</p>\n<p>But Wednesday’s earnings report and management updates may prove crucial to reinstill confidence among “Apes”.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GameStop Stock Could Soar After Its Recent Plunge. Here's Why. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGameStop Stock Could Soar After Its Recent Plunge. Here's Why. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 21:58 GMT+8 <a href=https://www.thestreet.com/memestocks/gme/heres-why-gme-stock-could-soar-after-its-recent-plunge><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Down more than 25% since late November, here’s what could happen next for the original meme stock.\nAs seen in recent days, GameStop stock has been affected by the stock market’s latest round of ...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/gme/heres-why-gme-stock-could-soar-after-its-recent-plunge\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站"},"source_url":"https://www.thestreet.com/memestocks/gme/heres-why-gme-stock-could-soar-after-its-recent-plunge","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196974870","content_text":"Down more than 25% since late November, here’s what could happen next for the original meme stock.\nAs seen in recent days, GameStop stock has been affected by the stock market’s latest round of volatility. Due to news of the Covid-19 Omicron variant, plus talk from the Federal Reserve about an end to its “easy money” policies, stocks across-the-board have declined since late November.\nDuring the same timeframe, shares in the video game retailer and “meme stock bluechip” have fallen by some 25%. But now, as Omicron worries may be fading, and volatility could soon clear up, what’s the next move for GameStop?\nFigure 1: GameStop store.\nPut simply, it’s debatable. Bulls can point to certain factors to support their views, as can bears. With this, let’s dive in, and explore what could push shares higher (or lower) from here.\nHow GME Stock Could Rebound After The Omicron Selloff\nWith its rapid drop during the week ending Dec 3, it may seem as if this stock is starting to lose its “unsinkable” reputation earned after holding onto most of its gains from its incredible run earlier this year.\nBut while many in the so-called “Ape army” may have trimmed/exited positions last week, there could be something that stops this latest selloff from being the beginning of the end for GME stock.\nThat would be the company’s upcoming earnings release on Dec 8. If coupled with a recovery from the Omicron selloff, shares could experience a big rebound in price.\nThis may be especially true if, along with better-than-expected earnings, the company releases more details about its e-commerce plans, plus other initiatives, such as its rumored move into NFTs (non-fungible tokens). News like it could help convince “Apes” still long the stock to maintain their positions, and convince others who got out after last week’s volatility to dive back into it.\nWhy The GameStop Price Collapse May Continue\nWhile it may be premature to say that many in the “Ape” community are ready to throw in the towel on GME stock, there is some evidence pointing in this direction.\nChatter on Reddit’s various stock-trading subreddits is dropping once again. Although according to ApeWisdom.io mentions are up 47% in the last 24 hours, the current level of discussion about it on the platform is down considerably from the elevated levels seen last month.\nThe main rationale behind holding this stock (to short-squeeze it) has fallen off as well. According to Fintel.io,short interest has dropped to just under 11%.\nGME’s waning appeal as a squeeze play may explain some of the frustration expressed by Reddit traders, after Fidelity Investments incorrectly stated the number of shares available to short through its platform.\nBottom Line\nBouncing between $160 and $170 per share today, it’s not definitive as to where GME stock is headed from here.\nBut Wednesday’s earnings report and management updates may prove crucial to reinstill confidence among “Apes”.","news_type":1,"symbols_score_info":{"GME":0.9}},"isVote":1,"tweetType":1,"viewCount":1345,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602389534,"gmtCreate":1638972240990,"gmtModify":1638972245822,"author":{"id":"3586429646894350","authorId":"3586429646894350","name":"IcyAlchemist","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586429646894350","idStr":"3586429646894350"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602389534","repostId":"2189642036","repostType":4,"repost":{"id":"2189642036","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1638972089,"share":"https://ttm.financial/m/news/2189642036?lang=&edition=full","pubTime":"2021-12-08 22:01","market":"us","language":"en","title":"Waymo's slow-going in Arizona opens up U.S. robotaxi race","url":"https://stock-news.laohu8.com/highlight/detail?id=2189642036","media":"Reuters","summary":"CHANDLER, Ariz., Dec 8 (Reuters) - Alphabet Inc's Waymo risks losing its lead in the U.S. race to pr","content":"<p>CHANDLER, Ariz., Dec 8 (Reuters) - Alphabet Inc's Waymo risks losing its lead in the U.S. race to prove robotaxis are a viable business as it sticks to a limited service and rivals backed by automakers near their own launches.</p>\n<p>Companies including Ford Motor Co's Argo AI and General Motors Co's Cruise are competing for the billions of dollars in financing needed to automate driving through artificial intelligence software and expensive sensors.</p>\n<p>Waymo has led the field. In the first and only fully driverless taxi service in the country, Waymo has driven thousands of people since opening a year ago east of Phoenix to anyone who downloads its ride-hailing app. And since August, hundreds in San Francisco have trialed cabs with safety drivers aboard.</p>\n<p>But Waymo lacks investment from a major automaker, which analysts say could hamper efforts to grow its fleet.</p>\n<p>Plans Waymo touted in 2018 to buy up to 62,000 Chrysler Pacifica minivans and 20,000 Jaguar I-Pace SUVs have not materialized. A big order for cameras to give eyes to its vehicles was scaled back, a person familiar with the matter said. Partnership talks in the past with automaker Hyundai Motor Co also fell through, another source said.</p>\n<p>Waymo's ride-hailing service in Arizona has not expanded beyond suburbs. It inquired about permitting for Phoenix airport rides in 2018 but has not pursued the process or approached San Francisco's airport at all, according to government records obtained by Reuters.</p>\n<p>Waymo cars still have lessons to learn. Some mall drop-offs in Arizona seen by Reuters blocked access to disabled parking spots for minutes in what disability advocates described as a potential legal violation.</p>\n<p>Raj Rajkumar, professor of electrical and computer engineering at Carnegie Mellon University, said high staffing costs also could contribute to Waymo's slow expansion. Riders in Arizona told Reuters that support crews in person or monitoring remotely have had to re-direct vehicles paralyzed by, among other sights, freight pallets, an errant stop sign and road-paving gear.</p>\n<p>Waymo has a different view.</p>\n<p>Partnerships with several automakers from around the world, rather than investment from just <a href=\"https://laohu8.com/S/AONE.U\">one</a>, serve what it describes as unparalleled ambitions across trucking, grocery delivery and more. Waymo said it has met all production goals, introduced hundreds of I-Pace crossovers.</p>\n<p>\"It would make little sense to place a bet on an individual OEM (equipment maker) - that would increase our risk and give us fewer future paths to market,\" the company said. \"The future of autonomy is about much more than ride-hail services.\"</p>\n<p>At the Reuters Next conference last week, Waymo Co-CEO Tekedra Mawakana said the company was in \"a robust phase of not only developing the technology but also developing commercial opportunities.\"</p>\n<p>\"There's a lot that goes into doing this the first time,\" she said. \"Then you build a playbook and it's just much easier to replicate it in future cities.\"</p>\n<p>Waymo recently began testing in central Phoenix, though without riders. It said personnel costs are not a determining factor in plans, and its system tries to avoid pulling over in disabled parking spots.</p>\n<p>Cruise aims to be permitted next year for a middle-of-the-night, driverless offering in San Francisco, and Tesla Inc Chief Executive Elon Musk continues to promise fully self-driving cars. Argo says it will partner with Lyft to open robotaxis in Miami before the new year - with a safety driver present.</p>\n<p>All the companies have missed targets or downsized plans, but some observers see a shift in Waymo's standing.</p>\n<p>\"Waymo is playing catch-up now,\" said Grayson Brulte, president at autonomous mobility consultancy Brulte & Co.</p>\n<p><b>WAYMO VS TESLA</b></p>\n<p>Born in 2009 as a project inside Google, Waymo has raised $5.75 billion in funding since 2020.</p>\n<p>Some analysts viewed the resignations this year of former CEO John Krafcik and other executives as a sign of Alphabet management's disappointment in slow progress, a charge Waymo denies. Krafcik remains an advisor.</p>\n<p>Waymo's strategy prioritizes safety and incorporating feedback. It has avoided a major accident, a testament to its caution.</p>\n<p>Hang Zhao, assistant professor at Tsinghua University and a former Waymo scientist, said that though it requires more engineers, Waymo has taken a safe approach to solving AI problems, especially in contrast to Tesla's tactics.</p>\n<p>Tesla did not respond to requests for comment.</p>\n<p>Swamy Kotagiri, chief executive of Waymo investor and auto industry supplier Magna International Inc , told analysts in July that he anticipates \"a long road\" for fully autonomous cars, adding that even by 2030 only \"a small number\" would be produced.</p>\n<p>Waymo's heady progress and optimism catalyzed the industry, with its then-chief Chris Urmson saying in 2015 that he expected his son to rely on autonomous vehicles in 2020.</p>\n<p>Urmson's new company Aurora, backed by big automakers, now targets 2024 to commercialize autonomous rides. But his earlier vision has come true, narrowly. In Chandler, the suburban hub of Waymo's commercial operation, Intel Corp engineer John Mitkowski is among residents commuting for work daily by driverless minivan.</p>\n<p>\"Just get in, go,\" Mitkowski said of his 3-mile, $8 Waymo trip each way.</p>\n<p>But he needs alternatives when flying or going to the nearby university or some favorite golf courses. His wife is too scared to ride in a robotaxi and his daughter, fresh out of university, opts for the convenience of her car.</p>\n<p>Waymo's limited supply in Arizona has led to 30-minute waits this year, according to customer Jordan Ranous, who has turned to rideshare service Lyft, where dinnertime trips cost $4 more for pick-up 26 minutes sooner.</p>\n<p>The majority of people opening Waymo's app see waits under 10 minutes, and ridership is growing, the company said.</p>\n<p>Mawakana, a half-year into her elevated role, said she has learned not to estimate timelines. She declined to predict when Waymo would drop safety drivers in San Francisco or might demonstrate profitability.</p>\n<p>\"What we've learned is it's not as important,\" she said of forecasts.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Waymo's slow-going in Arizona opens up U.S. robotaxi race</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWaymo's slow-going in Arizona opens up U.S. robotaxi race\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-08 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CHANDLER, Ariz., Dec 8 (Reuters) - Alphabet Inc's Waymo risks losing its lead in the U.S. race to prove robotaxis are a viable business as it sticks to a limited service and rivals backed by automakers near their own launches.</p>\n<p>Companies including Ford Motor Co's Argo AI and General Motors Co's Cruise are competing for the billions of dollars in financing needed to automate driving through artificial intelligence software and expensive sensors.</p>\n<p>Waymo has led the field. In the first and only fully driverless taxi service in the country, Waymo has driven thousands of people since opening a year ago east of Phoenix to anyone who downloads its ride-hailing app. And since August, hundreds in San Francisco have trialed cabs with safety drivers aboard.</p>\n<p>But Waymo lacks investment from a major automaker, which analysts say could hamper efforts to grow its fleet.</p>\n<p>Plans Waymo touted in 2018 to buy up to 62,000 Chrysler Pacifica minivans and 20,000 Jaguar I-Pace SUVs have not materialized. A big order for cameras to give eyes to its vehicles was scaled back, a person familiar with the matter said. Partnership talks in the past with automaker Hyundai Motor Co also fell through, another source said.</p>\n<p>Waymo's ride-hailing service in Arizona has not expanded beyond suburbs. It inquired about permitting for Phoenix airport rides in 2018 but has not pursued the process or approached San Francisco's airport at all, according to government records obtained by Reuters.</p>\n<p>Waymo cars still have lessons to learn. Some mall drop-offs in Arizona seen by Reuters blocked access to disabled parking spots for minutes in what disability advocates described as a potential legal violation.</p>\n<p>Raj Rajkumar, professor of electrical and computer engineering at Carnegie Mellon University, said high staffing costs also could contribute to Waymo's slow expansion. Riders in Arizona told Reuters that support crews in person or monitoring remotely have had to re-direct vehicles paralyzed by, among other sights, freight pallets, an errant stop sign and road-paving gear.</p>\n<p>Waymo has a different view.</p>\n<p>Partnerships with several automakers from around the world, rather than investment from just <a href=\"https://laohu8.com/S/AONE.U\">one</a>, serve what it describes as unparalleled ambitions across trucking, grocery delivery and more. Waymo said it has met all production goals, introduced hundreds of I-Pace crossovers.</p>\n<p>\"It would make little sense to place a bet on an individual OEM (equipment maker) - that would increase our risk and give us fewer future paths to market,\" the company said. \"The future of autonomy is about much more than ride-hail services.\"</p>\n<p>At the Reuters Next conference last week, Waymo Co-CEO Tekedra Mawakana said the company was in \"a robust phase of not only developing the technology but also developing commercial opportunities.\"</p>\n<p>\"There's a lot that goes into doing this the first time,\" she said. \"Then you build a playbook and it's just much easier to replicate it in future cities.\"</p>\n<p>Waymo recently began testing in central Phoenix, though without riders. It said personnel costs are not a determining factor in plans, and its system tries to avoid pulling over in disabled parking spots.</p>\n<p>Cruise aims to be permitted next year for a middle-of-the-night, driverless offering in San Francisco, and Tesla Inc Chief Executive Elon Musk continues to promise fully self-driving cars. Argo says it will partner with Lyft to open robotaxis in Miami before the new year - with a safety driver present.</p>\n<p>All the companies have missed targets or downsized plans, but some observers see a shift in Waymo's standing.</p>\n<p>\"Waymo is playing catch-up now,\" said Grayson Brulte, president at autonomous mobility consultancy Brulte & Co.</p>\n<p><b>WAYMO VS TESLA</b></p>\n<p>Born in 2009 as a project inside Google, Waymo has raised $5.75 billion in funding since 2020.</p>\n<p>Some analysts viewed the resignations this year of former CEO John Krafcik and other executives as a sign of Alphabet management's disappointment in slow progress, a charge Waymo denies. Krafcik remains an advisor.</p>\n<p>Waymo's strategy prioritizes safety and incorporating feedback. It has avoided a major accident, a testament to its caution.</p>\n<p>Hang Zhao, assistant professor at Tsinghua University and a former Waymo scientist, said that though it requires more engineers, Waymo has taken a safe approach to solving AI problems, especially in contrast to Tesla's tactics.</p>\n<p>Tesla did not respond to requests for comment.</p>\n<p>Swamy Kotagiri, chief executive of Waymo investor and auto industry supplier Magna International Inc , told analysts in July that he anticipates \"a long road\" for fully autonomous cars, adding that even by 2030 only \"a small number\" would be produced.</p>\n<p>Waymo's heady progress and optimism catalyzed the industry, with its then-chief Chris Urmson saying in 2015 that he expected his son to rely on autonomous vehicles in 2020.</p>\n<p>Urmson's new company Aurora, backed by big automakers, now targets 2024 to commercialize autonomous rides. But his earlier vision has come true, narrowly. In Chandler, the suburban hub of Waymo's commercial operation, Intel Corp engineer John Mitkowski is among residents commuting for work daily by driverless minivan.</p>\n<p>\"Just get in, go,\" Mitkowski said of his 3-mile, $8 Waymo trip each way.</p>\n<p>But he needs alternatives when flying or going to the nearby university or some favorite golf courses. His wife is too scared to ride in a robotaxi and his daughter, fresh out of university, opts for the convenience of her car.</p>\n<p>Waymo's limited supply in Arizona has led to 30-minute waits this year, according to customer Jordan Ranous, who has turned to rideshare service Lyft, where dinnertime trips cost $4 more for pick-up 26 minutes sooner.</p>\n<p>The majority of people opening Waymo's app see waits under 10 minutes, and ridership is growing, the company said.</p>\n<p>Mawakana, a half-year into her elevated role, said she has learned not to estimate timelines. She declined to predict when Waymo would drop safety drivers in San Francisco or might demonstrate profitability.</p>\n<p>\"What we've learned is it's not as important,\" she said of forecasts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4548":"巴美列捷福持仓","TSLA":"特斯拉","BK4551":"寇图资本持仓","UBER":"优步","BK4561":"索罗斯持仓","LYFT":"Lyft, Inc.","BK4527":"明星科技股","F":"福特汽车","BK4099":"汽车制造商","BK4534":"瑞士信贷持仓","BK4503":"景林资产持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4566":"资本集团","BK4536":"外卖概念","BK4022":"陆运","GM":"通用汽车","BK4505":"高瓴资本持仓","BK4535":"淡马锡持仓","GOOGL":"谷歌A","BK4559":"巴菲特持仓"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189642036","content_text":"CHANDLER, Ariz., Dec 8 (Reuters) - Alphabet Inc's Waymo risks losing its lead in the U.S. race to prove robotaxis are a viable business as it sticks to a limited service and rivals backed by automakers near their own launches.\nCompanies including Ford Motor Co's Argo AI and General Motors Co's Cruise are competing for the billions of dollars in financing needed to automate driving through artificial intelligence software and expensive sensors.\nWaymo has led the field. In the first and only fully driverless taxi service in the country, Waymo has driven thousands of people since opening a year ago east of Phoenix to anyone who downloads its ride-hailing app. And since August, hundreds in San Francisco have trialed cabs with safety drivers aboard.\nBut Waymo lacks investment from a major automaker, which analysts say could hamper efforts to grow its fleet.\nPlans Waymo touted in 2018 to buy up to 62,000 Chrysler Pacifica minivans and 20,000 Jaguar I-Pace SUVs have not materialized. A big order for cameras to give eyes to its vehicles was scaled back, a person familiar with the matter said. Partnership talks in the past with automaker Hyundai Motor Co also fell through, another source said.\nWaymo's ride-hailing service in Arizona has not expanded beyond suburbs. It inquired about permitting for Phoenix airport rides in 2018 but has not pursued the process or approached San Francisco's airport at all, according to government records obtained by Reuters.\nWaymo cars still have lessons to learn. Some mall drop-offs in Arizona seen by Reuters blocked access to disabled parking spots for minutes in what disability advocates described as a potential legal violation.\nRaj Rajkumar, professor of electrical and computer engineering at Carnegie Mellon University, said high staffing costs also could contribute to Waymo's slow expansion. Riders in Arizona told Reuters that support crews in person or monitoring remotely have had to re-direct vehicles paralyzed by, among other sights, freight pallets, an errant stop sign and road-paving gear.\nWaymo has a different view.\nPartnerships with several automakers from around the world, rather than investment from just one, serve what it describes as unparalleled ambitions across trucking, grocery delivery and more. Waymo said it has met all production goals, introduced hundreds of I-Pace crossovers.\n\"It would make little sense to place a bet on an individual OEM (equipment maker) - that would increase our risk and give us fewer future paths to market,\" the company said. \"The future of autonomy is about much more than ride-hail services.\"\nAt the Reuters Next conference last week, Waymo Co-CEO Tekedra Mawakana said the company was in \"a robust phase of not only developing the technology but also developing commercial opportunities.\"\n\"There's a lot that goes into doing this the first time,\" she said. \"Then you build a playbook and it's just much easier to replicate it in future cities.\"\nWaymo recently began testing in central Phoenix, though without riders. It said personnel costs are not a determining factor in plans, and its system tries to avoid pulling over in disabled parking spots.\nCruise aims to be permitted next year for a middle-of-the-night, driverless offering in San Francisco, and Tesla Inc Chief Executive Elon Musk continues to promise fully self-driving cars. Argo says it will partner with Lyft to open robotaxis in Miami before the new year - with a safety driver present.\nAll the companies have missed targets or downsized plans, but some observers see a shift in Waymo's standing.\n\"Waymo is playing catch-up now,\" said Grayson Brulte, president at autonomous mobility consultancy Brulte & Co.\nWAYMO VS TESLA\nBorn in 2009 as a project inside Google, Waymo has raised $5.75 billion in funding since 2020.\nSome analysts viewed the resignations this year of former CEO John Krafcik and other executives as a sign of Alphabet management's disappointment in slow progress, a charge Waymo denies. Krafcik remains an advisor.\nWaymo's strategy prioritizes safety and incorporating feedback. It has avoided a major accident, a testament to its caution.\nHang Zhao, assistant professor at Tsinghua University and a former Waymo scientist, said that though it requires more engineers, Waymo has taken a safe approach to solving AI problems, especially in contrast to Tesla's tactics.\nTesla did not respond to requests for comment.\nSwamy Kotagiri, chief executive of Waymo investor and auto industry supplier Magna International Inc , told analysts in July that he anticipates \"a long road\" for fully autonomous cars, adding that even by 2030 only \"a small number\" would be produced.\nWaymo's heady progress and optimism catalyzed the industry, with its then-chief Chris Urmson saying in 2015 that he expected his son to rely on autonomous vehicles in 2020.\nUrmson's new company Aurora, backed by big automakers, now targets 2024 to commercialize autonomous rides. But his earlier vision has come true, narrowly. In Chandler, the suburban hub of Waymo's commercial operation, Intel Corp engineer John Mitkowski is among residents commuting for work daily by driverless minivan.\n\"Just get in, go,\" Mitkowski said of his 3-mile, $8 Waymo trip each way.\nBut he needs alternatives when flying or going to the nearby university or some favorite golf courses. His wife is too scared to ride in a robotaxi and his daughter, fresh out of university, opts for the convenience of her car.\nWaymo's limited supply in Arizona has led to 30-minute waits this year, according to customer Jordan Ranous, who has turned to rideshare service Lyft, where dinnertime trips cost $4 more for pick-up 26 minutes sooner.\nThe majority of people opening Waymo's app see waits under 10 minutes, and ridership is growing, the company said.\nMawakana, a half-year into her elevated role, said she has learned not to estimate timelines. She declined to predict when Waymo would drop safety drivers in San Francisco or might demonstrate profitability.\n\"What we've learned is it's not as important,\" she said of forecasts.","news_type":1,"symbols_score_info":{"F":0.9,"GM":0.9,"GOOGL":0.9,"LYFT":0.9,"TSLA":0.9,"UBER":0.9}},"isVote":1,"tweetType":1,"viewCount":3185,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602389971,"gmtCreate":1638972220484,"gmtModify":1638972223651,"author":{"id":"3586429646894350","authorId":"3586429646894350","name":"IcyAlchemist","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586429646894350","idStr":"3586429646894350"},"themes":[],"htmlText":"Like and comment ","listText":"Like and comment ","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602389971","repostId":"1183863090","repostType":4,"repost":{"id":"1183863090","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638968845,"share":"https://ttm.financial/m/news/1183863090?lang=&edition=full","pubTime":"2021-12-08 21:07","market":"us","language":"en","title":"Toplines Before US Market Open on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1183863090","media":"Tiger Newspress","summary":"U.S. futures climbed for a third day after rising the most since March on Tuesday,as investors asses","content":"<p>U.S. futures climbed for a third day after rising the most since March on Tuesday,as investors assessed the uncertain effects of the Omicron variant on the economy.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 48 points, or 0.13%.The S&P 500 e-minis were up 8 points, or 0.17%, and Nasdaq 100 e-minis were up 38.25 points, or 0.23%.</p>\n<p><img src=\"https://static.tigerbbs.com/31985372e2ecc4486843a08080c6b077\" tg-width=\"1080\" tg-height=\"412\" width=\"100%\" height=\"auto\"></p>\n<p>Markets cheered news that BioNTech and Pfizer said that a three-shot course of their COVID-19 vaccine was shown to generate a neutralising effect against the new Omicron variant in a laboratory test.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p><b>Pfizer(PFE),BioNTech(BNTX)</b> – The companies said studies showed that three doses of their Covid-19 vaccine neutralized the omicron variant, while two doses still offered protection. Pfizer and BioNTech also said they’re continuing to work on an omicron-specific vaccine. Pfizer and BioNTech came well off earlier premarket lows on the news, with Pfizer up 0.7% and BioNTech trimming its loss to 1%.</p>\n<p><b>RLX Technology(RLX)</b> – RLX Technology announced that its board of directors has authorized a share repurchase program under which the Company may repurchase up to $500 million of its shares over a period until December 31, 2023.The shares jumped 9.7% in premarket trading.</p>\n<p><b>SentinelOne(</b><b>S</b><b>)</b> – SentinelOne stock plunged 10% in premarket trading after soaring 13.4% yesterday.SentinelOne reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.18) by 44.44 percent. This is a 69.41 percent increase over losses of $(0.85) per share from the same period last year. The company reported quarterly sales of $56.02 million which beat the analyst consensus estimate of $49.57 million by 13.01 percent.</p>\n<p><b>Stitch Fix(SFIX)</b> – Stitch was hammered by 24.3% in the premarket after issuing current-quarter revenue guidance and membership metrics that fell short of Wall Street forecasts. The online apparel retailer did post a narrower-than-expected loss for its latest quarter and better-than-expected revenue, but not enough to sway investor concerns.</p>\n<p><b>ChargePoint Holdings(CHPT)</b> – ChargePoint posted an adjusted loss of 14 cents per share for its latest quarter, 1 cent wider than anticipated, while the charging station network operator saw revenue slightly above estimates. The company did give stronger-than-expected current-quarter revenue guidance and raised its full-year outlook. Despite the upbeat outlook, ChargePoint fell 3.8% in premarket trading.</p>\n<p><b>PagerDuty(PD)</b> – PagerDuty reported an adjusted quarterly loss of 7 cents per share, 2 cents narrower than analysts had predicted, while revenue topped Street forecasts. The maker of IT response software also gave better-than-expected current-quarter revenue guidance, and its stock surged 11% in premarket action.</p>\n<p><b>Campbell Soup(CPB)</b> – The food producer beat estimates by 8 cents with adjusted quarterly earnings of 89 cents per share, although revenue was slightly below analyst forecasts. Campbell said demand remains elevated for its products, and that it’s been able to moderate the impact of higher input costs through strong pricing and productivity improvements. The stock fell 0.6% in the premarket.</p>\n<p><b>Thor Industries(THO)</b> – The recreational vehicle maker earned $4.34 per share for its latest quarter, well above the $3.24 consensus estimate. Revenue was also above Wall Street forecasts amid continued strong demand. Thor rose 2.5% in premarket trading.</p>\n<p><b>Weber(WEBR)</b> – The grill maker’s stock jumped 10.3% in the premarket after it reported a narrower-than-expected loss for its latest quarter and beat Wall Street revenue forecasts. Weber lost 13 cents per share, 5 cents less than analysts had anticipated.</p>\n<p><b>Toll Brothers(TOL)</b> – Toll Brothers earned $3.02 per share for its latest quarter, compared with a consensus estimate of $2.49, while the luxury home builder also reported better-than-expected revenue. It is also projecting 20% growth in fiscal 2022 revenue as demand remains elevated. Toll added 2.1% in the premarket.</p>\n<p><b>BlackRock(BLK)</b> – The asset management firm is pulling about $2 trillion of assets from <b>State Street(STT)</b>, which had served as the sole custodian of BlackRock’s ETFs. BlackRock will be shifting some of its ETF custodianship to <b>Citigroup(C)</b>,<b>JPMorgan Chase(JPM)</b> and <b>Bank of America(BAC)</b>.</p>\n<p><b>Dave & Buster’s</b><b>(PLAY)</b> – Dave & Buster’s beat estimates by 8 cents with a quarterly profit of 23 cents per share, while the operator of entertainment center-themed restaurants also saw revenue come in above Street forecasts. Dave & Buster’s rallied 5.6% in the premarket.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 21:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. futures climbed for a third day after rising the most since March on Tuesday,as investors assessed the uncertain effects of the Omicron variant on the economy.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 48 points, or 0.13%.The S&P 500 e-minis were up 8 points, or 0.17%, and Nasdaq 100 e-minis were up 38.25 points, or 0.23%.</p>\n<p><img src=\"https://static.tigerbbs.com/31985372e2ecc4486843a08080c6b077\" tg-width=\"1080\" tg-height=\"412\" width=\"100%\" height=\"auto\"></p>\n<p>Markets cheered news that BioNTech and Pfizer said that a three-shot course of their COVID-19 vaccine was shown to generate a neutralising effect against the new Omicron variant in a laboratory test.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p><b>Pfizer(PFE),BioNTech(BNTX)</b> – The companies said studies showed that three doses of their Covid-19 vaccine neutralized the omicron variant, while two doses still offered protection. Pfizer and BioNTech also said they’re continuing to work on an omicron-specific vaccine. Pfizer and BioNTech came well off earlier premarket lows on the news, with Pfizer up 0.7% and BioNTech trimming its loss to 1%.</p>\n<p><b>RLX Technology(RLX)</b> – RLX Technology announced that its board of directors has authorized a share repurchase program under which the Company may repurchase up to $500 million of its shares over a period until December 31, 2023.The shares jumped 9.7% in premarket trading.</p>\n<p><b>SentinelOne(</b><b>S</b><b>)</b> – SentinelOne stock plunged 10% in premarket trading after soaring 13.4% yesterday.SentinelOne reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.18) by 44.44 percent. This is a 69.41 percent increase over losses of $(0.85) per share from the same period last year. The company reported quarterly sales of $56.02 million which beat the analyst consensus estimate of $49.57 million by 13.01 percent.</p>\n<p><b>Stitch Fix(SFIX)</b> – Stitch was hammered by 24.3% in the premarket after issuing current-quarter revenue guidance and membership metrics that fell short of Wall Street forecasts. The online apparel retailer did post a narrower-than-expected loss for its latest quarter and better-than-expected revenue, but not enough to sway investor concerns.</p>\n<p><b>ChargePoint Holdings(CHPT)</b> – ChargePoint posted an adjusted loss of 14 cents per share for its latest quarter, 1 cent wider than anticipated, while the charging station network operator saw revenue slightly above estimates. The company did give stronger-than-expected current-quarter revenue guidance and raised its full-year outlook. Despite the upbeat outlook, ChargePoint fell 3.8% in premarket trading.</p>\n<p><b>PagerDuty(PD)</b> – PagerDuty reported an adjusted quarterly loss of 7 cents per share, 2 cents narrower than analysts had predicted, while revenue topped Street forecasts. The maker of IT response software also gave better-than-expected current-quarter revenue guidance, and its stock surged 11% in premarket action.</p>\n<p><b>Campbell Soup(CPB)</b> – The food producer beat estimates by 8 cents with adjusted quarterly earnings of 89 cents per share, although revenue was slightly below analyst forecasts. Campbell said demand remains elevated for its products, and that it’s been able to moderate the impact of higher input costs through strong pricing and productivity improvements. The stock fell 0.6% in the premarket.</p>\n<p><b>Thor Industries(THO)</b> – The recreational vehicle maker earned $4.34 per share for its latest quarter, well above the $3.24 consensus estimate. Revenue was also above Wall Street forecasts amid continued strong demand. Thor rose 2.5% in premarket trading.</p>\n<p><b>Weber(WEBR)</b> – The grill maker’s stock jumped 10.3% in the premarket after it reported a narrower-than-expected loss for its latest quarter and beat Wall Street revenue forecasts. Weber lost 13 cents per share, 5 cents less than analysts had anticipated.</p>\n<p><b>Toll Brothers(TOL)</b> – Toll Brothers earned $3.02 per share for its latest quarter, compared with a consensus estimate of $2.49, while the luxury home builder also reported better-than-expected revenue. It is also projecting 20% growth in fiscal 2022 revenue as demand remains elevated. Toll added 2.1% in the premarket.</p>\n<p><b>BlackRock(BLK)</b> – The asset management firm is pulling about $2 trillion of assets from <b>State Street(STT)</b>, which had served as the sole custodian of BlackRock’s ETFs. BlackRock will be shifting some of its ETF custodianship to <b>Citigroup(C)</b>,<b>JPMorgan Chase(JPM)</b> and <b>Bank of America(BAC)</b>.</p>\n<p><b>Dave & Buster’s</b><b>(PLAY)</b> – Dave & Buster’s beat estimates by 8 cents with a quarterly profit of 23 cents per share, while the operator of entertainment center-themed restaurants also saw revenue come in above Street forecasts. Dave & Buster’s rallied 5.6% in the premarket.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index","BLK":"贝莱德","WEBR":"Weber Inc.","RLX":"雾芯科技","THO":"索尔工业","TOL":"托尔兄弟","PFE":"辉瑞","CPB":"金宝汤","PD":"PagerDuty, Inc.","CHPT":"ChargePoint Holdings Inc.","STT":"道富银行","SFIX":"Stitch Fix Inc.","S":"SentinelOne, Inc","BNTX":"BioNTech SE",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","PLAY":"Dave & Buster"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183863090","content_text":"U.S. futures climbed for a third day after rising the most since March on Tuesday,as investors assessed the uncertain effects of the Omicron variant on the economy.\nAt 8:00 a.m. ET, Dow e-minis were up 48 points, or 0.13%.The S&P 500 e-minis were up 8 points, or 0.17%, and Nasdaq 100 e-minis were up 38.25 points, or 0.23%.\n\nMarkets cheered news that BioNTech and Pfizer said that a three-shot course of their COVID-19 vaccine was shown to generate a neutralising effect against the new Omicron variant in a laboratory test.\nStocks making the biggest moves premarket:\nPfizer(PFE),BioNTech(BNTX) – The companies said studies showed that three doses of their Covid-19 vaccine neutralized the omicron variant, while two doses still offered protection. Pfizer and BioNTech also said they’re continuing to work on an omicron-specific vaccine. Pfizer and BioNTech came well off earlier premarket lows on the news, with Pfizer up 0.7% and BioNTech trimming its loss to 1%.\nRLX Technology(RLX) – RLX Technology announced that its board of directors has authorized a share repurchase program under which the Company may repurchase up to $500 million of its shares over a period until December 31, 2023.The shares jumped 9.7% in premarket trading.\nSentinelOne(S) – SentinelOne stock plunged 10% in premarket trading after soaring 13.4% yesterday.SentinelOne reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.18) by 44.44 percent. This is a 69.41 percent increase over losses of $(0.85) per share from the same period last year. The company reported quarterly sales of $56.02 million which beat the analyst consensus estimate of $49.57 million by 13.01 percent.\nStitch Fix(SFIX) – Stitch was hammered by 24.3% in the premarket after issuing current-quarter revenue guidance and membership metrics that fell short of Wall Street forecasts. The online apparel retailer did post a narrower-than-expected loss for its latest quarter and better-than-expected revenue, but not enough to sway investor concerns.\nChargePoint Holdings(CHPT) – ChargePoint posted an adjusted loss of 14 cents per share for its latest quarter, 1 cent wider than anticipated, while the charging station network operator saw revenue slightly above estimates. The company did give stronger-than-expected current-quarter revenue guidance and raised its full-year outlook. Despite the upbeat outlook, ChargePoint fell 3.8% in premarket trading.\nPagerDuty(PD) – PagerDuty reported an adjusted quarterly loss of 7 cents per share, 2 cents narrower than analysts had predicted, while revenue topped Street forecasts. The maker of IT response software also gave better-than-expected current-quarter revenue guidance, and its stock surged 11% in premarket action.\nCampbell Soup(CPB) – The food producer beat estimates by 8 cents with adjusted quarterly earnings of 89 cents per share, although revenue was slightly below analyst forecasts. Campbell said demand remains elevated for its products, and that it’s been able to moderate the impact of higher input costs through strong pricing and productivity improvements. The stock fell 0.6% in the premarket.\nThor Industries(THO) – The recreational vehicle maker earned $4.34 per share for its latest quarter, well above the $3.24 consensus estimate. Revenue was also above Wall Street forecasts amid continued strong demand. Thor rose 2.5% in premarket trading.\nWeber(WEBR) – The grill maker’s stock jumped 10.3% in the premarket after it reported a narrower-than-expected loss for its latest quarter and beat Wall Street revenue forecasts. Weber lost 13 cents per share, 5 cents less than analysts had anticipated.\nToll Brothers(TOL) – Toll Brothers earned $3.02 per share for its latest quarter, compared with a consensus estimate of $2.49, while the luxury home builder also reported better-than-expected revenue. It is also projecting 20% growth in fiscal 2022 revenue as demand remains elevated. Toll added 2.1% in the premarket.\nBlackRock(BLK) – The asset management firm is pulling about $2 trillion of assets from State Street(STT), which had served as the sole custodian of BlackRock’s ETFs. BlackRock will be shifting some of its ETF custodianship to Citigroup(C),JPMorgan Chase(JPM) and Bank of America(BAC).\nDave & Buster’s(PLAY) – Dave & Buster’s beat estimates by 8 cents with a quarterly profit of 23 cents per share, while the operator of entertainment center-themed restaurants also saw revenue come in above Street forecasts. Dave & Buster’s rallied 5.6% in the premarket.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"BLK":0.9,"BNTX":0.9,"CHPT":0.9,"CPB":0.9,"ESmain":0.9,"NQmain":0.9,"YMmain":0.9,"PD":0.9,"PFE":0.9,"PLAY":0.9,"RLX":0.9,"S":0.9,"SFIX":0.9,"STT":0.9,"THO":0.9,"TOL":0.9,"WEBR":0.9}},"isVote":1,"tweetType":1,"viewCount":1454,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}